Europe PMC Funders Group

Author Manuscript

Cochrane Database Syst Rev. Author manuscript; available in PMC 2014 September 15.

Published in final edited form as:

Cochrane Database Syst Rev. 2004; (3): CD003331. doi:10.1002/14651858.CD003331.pub2.

Exercise based rehabilitation for heart failure

Karen Rees¹, Rod RS Taylor², Sally Singh³, Andrew JS Coats⁴, and Shah Ebrahim⁵

¹Department of Social Medicine, University of Bristol, Bristol, UK

²PenTAG, Peninsula Medical School, Exeter, UK

³Head of Cardiac & Pulmonary Rehabilitation Glenfield Hospital Leicester, UK

⁴University of Sydney, Sydney, Australia

⁵Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK

Abstract

Background—The prevalence of chronic heart failure is increasing, and increases with increasing age. Major symptoms include breathlessness and restricted activities of daily living due to reduced functional capacity, which in turn affects quality of life. Exercise training has been shown to be effective in patients with coronary heart disease and has been proposed as an intervention to improve exercise tolerance in patients with heart failure.

Objectives—To determine the effectiveness of exercise based interventions compared with usual medical care on the mortality, morbidity, exercise capacity and health related quality of life, of patients with heart failure.

Search strategy—We searched the Cochrane Controlled Trials Register (*The Cochrane Library* Issue 2, 2001), MEDLINE (2000 to March 2001), EMBASE (1998 to March 2001), CINAHL (1984 to March 2001) and reference lists of articles. We also sought advice from experts.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

Contact address: Karen Rees, Department of Social Medicine, University of Bristol, Whiteladies Road, Bristol, BS3 1AZ, UK. rees karen@yahoo.co.uk.

Editorial group: Cochrane Heart Group.

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009.

Review content assessed as up-to-date: 17 May 2004.

CONTRIBUTIONS OF AUTHORS: All co-reviewers were involved in the design of the review and in providing critical comments about the manuscript. Karen Rees and Rod Taylor independently selected studies for inclusion, extracted data from the source papers and analysed the data. Andrew Coats and Sally Singh provided clinical expertise. Shah Ebrahim acted as the principal advisor.

DECLARATIONS OF INTEREST

RT - former chair of BACR Scientific Sub-Committee, written a number of publications in the field of cardiac rehabilitation and currently involved in two UK RCTs of cardiac rehabilitation.

AC - author of 2 of the included trials, and a number of papers in the field of heart failure.

NOTES

The Peninsula Technology Assessment Group (PenTAG) at Peninsula Medical School, Exeter, UK and the Cochrane Heart Group have been awarded a 3-year grant from the National Institute for Health Research to update existing Cochrane systematic reviews relevant to public health, primary care and rehabilitation.

This review is scheduled to be updated in the first year of the program. Publication of the updated review is anticipated by issue 2, 2009 at the latest.

Selection criteria—RCTs of exercise based interventions. The comparison group was usual medical care as defined by the study, or placebo. Adults of all ages with chronic heart failure. Only those studies with criteria for diagnosis of heart failure (based on clinical findings or objective indices) have been included.

Data collection and analysis—Studies were selected, and data were abstracted, independently by two reviewers. Authors were contacted where possible to obtain missing information.

Main results—Twenty-nine studies met the inclusion criteria, with 1126 patients randomised. The majority of studies included both patients with primary and secondary heart failure, NYHA class II or III. Only one study specifically examined the effect of exercise training on mortality and morbidity. Exercise training significantly increased VO₂ max by (WMD random effects model) 2.16 ml/kg/min (95% CI 2.82 to 1.49), exercise duration increased by 2.38 minutes (95% CI 2.85 to 1.9), work capacity by 15.1 Watts (95% CI 17.7 to 12.6) and distance on the six minute walk by 40.9 metres (95% CI 64.7 to 17.1). Improvements in VO₂ max were greater for training programmes of greater intensity and duration. HRQoL improved in the seven of nine trials that measured this outcome.

Authors' conclusions—Exercise training improves exercise capacity and quality of life in patients mild to moderate heart failure in the short term. One study found beneficial effects of exercise on cardiac mortality and hospital readmissions over 3 years of follow-up, the remaining included studies did not aim to measure clinical outcomes and were of short duration. The findings of the review are based on small-scale trials in patients who are unrepresentative of the total population of patients with heart failure. Other groups (more severe patients, the elderly, women) may also benefit. Large-scale pragmatic trials of exercise training of longer duration, recruiting a wider spectrum of patients are needed to address these issues.

Medical Subject Headings (MeSH)

*Exercise Therapy; Cardiac Output, Low [*rehabilitation; therapy]; Chronic Disease; Heart Failure [*rehabilitation; therapy]; Quality of Life; Randomized Controlled Trials as Topic

MeSH check	words			
Humans				

BACKGROUND

The prevalence and incidence of chronic heart failure (CHF) is steadily increasing with approximately 550,000 new cases annually in the United States (AHA). Whilst improved management of hypertension has reduced this condition as an aetiological factor in the development of heart failure, the increased survival rate from myocardial infarction has lead to a subsequent increase in the number of cases of chronic heart failure (Kostis 1997), as has increasing longevity in developed countries. In the developing world the occurrence of heart failure can often be attributed to valvular heart disease and nutritional cardiac disease (Lip 2000). Estimates of the prevalence of heart failure in Europe range from 0.4 to 2% in middle aged adults (Cowie 1997), but over 65 years of age the prevalence of CHF is in the region of

6 to 10%. (Kannel 1991). Hospital admission rates for heart failure are rising in all industrialised countries, particularly among the elderly (McMurray 2000).

Patients with heart failure present with a variety of symptoms most of which are often non specific (Watson 2000). The most frequently presenting symptom is exertional breathlessness. Additional important symptoms may be fatigue and lethargy, in addition to swelling of the feet and ankles. Symptoms and functional exercise capacity are used to classify the severity of heart failure (using the New York Heart Association (NYHA) classification) and judge the response to treatment. Whilst the classification of severity is based upon symptoms, the diagnosis is secured with objective measures. The European Task Force report (CHF Taskforce 2001) proposes that the definition of heart failure should rely on two criteria: symptoms of heart failure at rest or during exercise (typically breathlessness and fatigue) and objective evidence of cardiac dysfunction at rest. Where the diagnosis is in doubt, a response to treatment directed towards heart failure may also be used in addition to the above criteria. However, like many chronic diseases there is a poor correlation between symptoms and the degree of cardiac impairment, and also between symptoms and disease prognosis (Hülsmann 2002; Opasich 2001; van den Brock 1992).

Coupled with the pathological changes of heart failure and associated symptoms is a reduction in exercise tolerance due to impaired skeletal muscle function. Muscle function depends upon perfusion, muscle mass, fibre composition and energy metabolism - alteration of any of these will influence physical performance. Muscle performance can be defined as either strength or endurance and both can be reduced in chronic heart failure. For heart failure there is reduced capillary fibre ratio, reduced peripheral blood flow and an alteration in mitochondrial density, leading to a reduced oxidative capacity of the peripheral muscle (Drexler 1992; Mancini 1992; Sullivan 1989). Inactivity contributes to these changes. Decreased exercise capacity restricts activities of daily living, this in turn influences an individual's independence and quality of life.

The management of chronic heart failure is characterised by a combination of drugs and lifestyle changes. Drug therapy aims to control symptoms by controlling fluid balance and blocking neurohormonal activation. Lifestyle management is important in chronic heart failure and includes diet and exercise. Decreased exercise capacity is the main factor restricting daily activity for this patient group. Patients become trapped in a vicious circle of inactivity and decreasing functional capacity. Historically patients with heart failure were advised to avoid exertion for fear of worsening cardiac function due to myocardial stress. In the late 1970s and early 1980s it was reported that exercise training was safe in patients with impaired ventricular function. These studies reported a significant improvement in work capacity after training (Conn 1982; Lee 1979). In 1990 Coats and colleagues demonstrated a beneficial effect of exercise training on exercise tolerance, peak oxygen consumption and symptoms in a cross over trial of patients with heart failure, and concluded that rest as the mainstay of treatment for chronic heart failure should no longer be accepted (Coats 1990). This has been confirmed in a number of trials subsequently (e.g. Keteyian 1996; Kiilavuori 1996,). More recently studies have focused on the central and peripheral physiological changes after precisely prescribed exercise regimens. The positive effects of exercise training are thought to occur mainly peripherally in skeletal muscle. These include reduced

lactate production (delayed onset of anaerobic metabolism), improved aerobic capacity, reduced sympathetic drive and increased vagal tone (Belardinelli 1992; Coats 1992; Hambrecht 1995; Tyni-Lenne/Gordon 96). Ventilatory parameters also improve. Changes in peak oxygen consumption are consistently documented as are improved anaerobic threshold and decreases in the ventilatory equivalent for carbon dioxide (Tyni-Lenne 2001; Wielenga 1999 CHANGE). Some central cardio-vascular changes have been reported such as improved myocardial perfusion (Belardinelli 1999), improved cardiac output at submaximal work rates (Coats 1992), associated reduction in peak heart rates (Keteyian 1996) and improved peripheral blood flow (Dziekan 1998; Sullivan 1988).

The effectiveness of exercise based rehabilitation in patients with coronary heart disease (CHD) has been demonstrated in two early meta-analyses (Oldridge 1988; O'Connor 1989), and in an updated recent Cochrane systematic review (Jolliffe 2001). These systematic reviews specifically excluded patients with heart failure. Exercise based rehabilitation significantly reduces all cause and cardiac mortality, cholesterol and cigarette smoking in patients with CHD (Jolliffe 2001). The provision of cardiac rehabilitation for patients with CHD in the UK is required by recent policy (National Service Framework for Coronary Heart disease - Standard 12, DOH 2000). It is suggested that cardiac rehabilitation should also be considered as an option for patients with heart failure who may potentially benefit (Standard 11, DOH 2000). Currently, patients with heart failure are underrepresented in cardiac rehabilitation programmes (NHS 1998).

The current review in a series on cardiac rehabilitation (Jolliffe 2001; Rees 2004) will concentrate on exercise based interventions for heart failure. The effectiveness of exercise based rehabilitation for patients with heart failure has been examined in a recent qualitative overview where the authors found beneficial effects on physical performance in 27 of 31 studies identified, on mortality in 1 of 31 studies, and of quality of life in 1 of 16 studies (Lloyd-Williams 2002). Whilst this review was comprehensive in its search strategy in that many data sources were searched, it did exclude non-English language publications, it included non randomised and before and after studies (only 22 of 31 studies were randomised controlled trials), and made no attempt to pool data statistically from those trials which were identified. Thus no estimate of effect size for exercise interventions for CHF patients was obtained for any outcome examined. Furthermore, several randomised controlled trials have been published which were not included in the above review.

OBJECTIVES

To determine the effectiveness of exercise based interventions compared with usual medical care on the mortality, morbidity, exercise capacity and health related quality of life, of patients with heart failure. A secondary objective was to examine any adverse events associated with exercise in these patients.

METHODS

Criteria for considering studies for this review

Types of studies—Randomised controlled trials either a parallel group or cross-over design.

Types of participants—All adults with chronic heart failure. Only those studies with criteria for diagnosis of heart failure (based on clinical findings or objective indices) have been included. Where possible we have distinguished between patients with primary heart failure (dilated cardiomyopathy - DCM), and those with heart failure secondary to coronary heart disease (CHD). Studies including patients who have previously been offered cardiac rehabilitation for either myocardial infarction or heart failure have been excluded.

Types of interventions—Exercise based interventions, either alone or as a component of comprehensive cardiac rehabilitation (defined as programmes including also other components such as health education and psychological interventions, in addition to exercise interventions). The comparison group was usual medical care as defined by the study, or an "attention placebo".

Types of outcome measures

- 1. All cause mortality;
- 2. Morbidity non-fatal myocardial infarction, revascularisation;
- 3. Hospital admissions/re-hospitalisation;
- 4. Exercise capacity;
- 5. Physical activity levels;
- **6.** Validated measures of health related quality of life (HRQoL).

Search methods for identification of studies

We searched the Cochrane Controlled Trials Register (*The Cochrane Library* Issue 2, 2001) using the strategy outlined below. This was updated by searching MEDLINE (2000 to March 2001) on Ovid using a standard RCT filter (Dickersin 1994) and EMBASE (1998 to March 2001) using an EMBASE RCT filter (Lefebvre 1996) and searching CINAHL (1984 to March 2001). In addition, we searched reference lists of articles and sought expert advice. No language restrictions were applied.

CCTR Search Strategy

- 1. HEART-FAILURE-CONGESTIVE*:ME
- 2. (HEART and FAILURE)
- **3.** (CARDIAC and FAILURE)
- **4.** ((#1 or #2) or #3)
- 5. REHABILITATION*:ME

- **6.** EXERCISE*:ME
- 7. EXERCISE-THERAPY*:ME
- 8. SPORTS*:ME
- 9. PHYSICAL-EDUCATION-AND-TRAINING*:ME
- 10. EXERTION*:ME
- 11. REHABILITAT*
- **12.** (PHYSICAL* near FIT)
- 13. (PHYSICAL* near FITNESS)
- 14. (PHYSICAL near TRAIN*)
- 15. (PHYSICAL* near ACTIVIT*)
- **16.** (TRAIN* near STRENGTH*)
- 17. (TRAIN* near AEROBIC*)
- 18. (AEROBIC* near EXERCISE*)
- 19. KINESIOTHERAP*
- 20. (EXERCISE* near TRAIN*)
- 22. (#4 and #21)

Data collection and analysis

Study selection—From the searches, the title and abstract of each paper was reviewed by one reviewer (KR) and potentially relevant references retrieved. Following this initial screening, two reviewers (KR, RT) independently selected trials to be included in this review using predetermined inclusion criteria. In all cases disagreements about any study inclusions were resolved by consensus. The general agreement for two raters over all categories (study included, excluded or pending) was assessed by Cohen's kappa (weighted). Observed agreement was 88.3%, expected agreement 54%, Kappa = 0.75 (95% confidence interval = 0.57 to 0.93). The quality of trials was assessed in terms of concealment of allocation, losses to follow up, and blind assessment of outcomes. Quality was also assessed by using the Jadad Scale (Jadad 1996).

Data extraction—Study outcome data were extracted by one reviewer (KR) and chief investigators were contacted to provide additional relevant information. Data extraction was checked by a second reviewer (RT) in a random sample of 10 studies.

Data analysis—Dichotomous outcomes were expressed as odds ratios, and 95% confidence intervals (CI) were calculated for each study. For continuous variables net changes were compared (i.e. control group minus intervention group differences) and a

weighted mean difference (WMD) or standardised mean difference (SMD) and 95% CI have been calculated for each study. Where standard deviation differences were not reported in the source papers, allowance has been made for within patient correlation from baseline to follow up measurements by using the correlation coefficient between the two (Cochrane Heart Group; Follmann 1992).

For cross-over trials, data from the first arm only has been included. Where data for the two arms is combined then this has been accepted only if the authors state there are no carryover effects, or there is evidence of washout.

For each outcome, a test of heterogeneity was carried out. In the situation of no heterogeneity, fixed effects meta-analysis was used. If substantial heterogeneity (p<0.1) was detected, the reviewers looked for possible explanations (e.g. participants and intervention) for this. If the heterogeneity could not be explained, the reviewers considered the following options: not to aggregate the studies at all, or use a random effects model with appropriate cautious interpretation. Where a random effects model has been used this is indicated in parentheses.

Stratified analyses and meta-regression were used to examine the effect of intensity of the intervention, age, duration of follow up and trial quality on the outcome VO_2 max, the outcome most frequently reported in the included studies. These subgroups were defined in advance. Sensitivity analysis was carried out to examine the effect of excluding the few studies which did not include an aerobic training component.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

From the searching, 1162 studies were found, the title and abstracts of these were screened and 79 went forward for formal inclusion or exclusion. Thirty three separate trials met the inclusion criteria. Of these, 4 were later excluded; 3 because of insufficient data despite contacting the authors to obtain information, and one because of overlap in the participants recruited in another included study. Data from the remaining 29 studies with 1126 patients randomised were used in the analyses. Of these 29 trials, 23 evaluate an aerobic intervention and 6 report resistance training of peripheral muscle groups. Twenty three of the trials are parallel group design, the remaining 6 are cross over trials. The majority of trials include both patients with primary (dilated cardiomyopathy) and secondary (ischemic heart disease) heart failure, with only 4 trials reporting these patient groups separately. All patients included met the New York Heart Association (NYHA) criteria for symptoms (class II or III) and all had a left ventricular ejection fraction (LVEF) < 40%. The mean age of participants across the included studies ranged from 51 to 77 years. Most studies recruited predominantly male patients with the exception of two studies that recruited only women (Pu 2001; Tyni-Lenne 1997). Mean follow up was 20 (SD 14) weeks (range 4 to 60 weeks) for exercise variables and quality of life. One study reported clinical data at 3.3 years of follow-up (Belardinelli 1999).

Details of the studies included in the review are shown in the table 'Characteristics of included studies'. Reasons for exclusion are presented in the table 'Characteristics of excluded studies'.

Risk of bias in included studies

The methodological quality of the included studies are presented in Table 01. The methodological quality of trials in terms of the method of randomisation, allocation concealment, blinding of outcome assessors and losses to follow up, is as was reported in the papers. For the majority of studies, both the method of randomisation, and the method of allocation concealment were unclear. Most of the trials were short term studies and so therefore the loss to follow up was low, with the exception of five trials where this was greater than 20%. The median Jadad score for the 34 trials was 2 (interquartile range 2 to 3, range 1 to 4), out of a possible score of 5 (Jadad 1996). The Jadad score has been used as an overall indicator of trial quality in the stratified analyses to examine its impact on outcome (see results section).

Effects of interventions

Clinical events—Only one study with long term follow-up aimed to examine the effect of exercise on mortality and morbidity (Belardinelli 1999). This study showed that cardiac mortality was statistically significantly reduced with the exercise intervention over 3.3 years of follow-up (99 patients randomised, odds ratio 0.32 (95% CI 0.13, 0.8)), as were hospital readmissions for heart failure (odds ratio 0.28 (95% CI 0.09, 0.85)). There was no statistically significant effect of the intervention on non-fatal myocardial infarction (odds ratio 0.48 (95% CI 0.04, 5.47)).

Several studies report deaths as dropouts during the study period, which the authors state were unrelated to the intervention (Gottlieb 1999; Hambrecht 1995; Hambrecht 1998; Hambrecht 2000; Owen 2000; Ponikowski 1997; Teo 1995 EXERT; Wielenga 1999 CHANGE). Nonetheless, if we pool this data for all cause mortality there is no significant difference between the intervention and control groups (odds ratio 1.12 (95% CI 0.58 to 2.15)). The follow-up period for these trials ranged from 16 to 52 weeks. One study reported a non-fatal MI in the control group (Ponikowski 1997), none of the studies report other clinical events.

Adverse events—Whilst not a primary objective of the review, all studies were examined for reports of any adverse events during exercise training. Adverse events were those as defined by the authors, and/or clinical events (including deaths, myocardial infarction, arrhythmias) reported to be associated with exercise training. The majority of studies state that there were no adverse events associated with the intervention (17 of 29 studies), although these studies were not designed to examine safety, nor did they state in their objectives that they would do so. Only one trial reported complications associated with training, but these were confined to the most severe patients with ejection fractions below 30% (Jette 1991).

Exercise variables—For all variables concerned with exercise capacity, an increase in value from baseline to follow-up indicates improvement with the exercise intervention. For this reason, the sign of the mean change in these variables for both the intervention and control groups has been changed for the pooled analysis so the direction of effect is in the appropriate direction on the Metaview plots.

VO₂ max was measured in 24 studies (848 participants randomised) and improved markedly with exercise training by 2.16 ml/kg/min (WMD random effects model, 95% CI 2.82 to 1.49). Similar significant improvements were seen for exercise duration measured in 15 studies (510 participants randomised) which increased by 2.38 minutes (WMD 95% CI 2.85 to 1.92), and maximum work capacity measured in six studies (219 participants randomised) which increased by 15.1 Watts (WMD 95% CI 17.7 to 12.6) in the training group. Distance on the six minute walk was measured in eight studies (282 participants randomised) which increased by 40.9 metres (WMD random effects model 95% CI 64.7 to 17.1). Heterogeneity between studies for this outcome is due to one trial (Teo 1995 EXERT) that showed no effect of intervention, whilst the remaining seven showed large positive effects. This trial measured outcomes over the short (3 months) and longer term (12 months) and results were similar for both time periods.

Subgroup analyses—Marked heterogeneity was seen for the outcome VO_2 max (chi square 61.27, p < 0.00001), and to explore this further we carried out a number of prespecified subgroup analyses. The cut-off points used for each explanatory variable were the median values for the studies reporting this outcome.

The variables thought to have an impact on heterogeneity between studies included

- the intensity of the intervention ("Dose" calculated as the number of weeks
 multiplied by the number of sessions per week, multiplied by the duration of
 sessions in hours);
- duration of the intervention;
- trial quality assessed by the Jadad score (determined from what was reported in the papers);
- · duration of follow-up and
- mean age.

The "dose" of the intervention varied from 3 to 112 units (mean 40.3 SD 30.7), and the duration of the intervention varied from 3 to 52 weeks (mean 16 SD 11.5) across the studies.

Interventions of greater intensity had a larger effect on the improvements seen in VO_2 max but the 95% CI's overlapped with lower doses suggesting that the difference between the two was not statistically significant (Dose > 30 units WMD, random effects model 2.78 (95% CI 3.88 to 1.69)), Dose < 30 units WMD 1.64 (95% CI 2.2 to 1.1). Slightly larger effects on VO_2 max were seen with studies of poorer methodological quality (Jadad score 2 and below), but this was not statistically significant. The improvement in VO_2 max was greater in patients aged less than 55 years WMD 2.95 (95% CI 4.25 to 1.64) versus greater

than 55 years WMD 1.77 (95% CI 2.5 to 1.03), but again this does not reach statistical significance. Age is reported in all studies as an aggregate measure and thus comparison between these two age groups may be misleading as individual patient data are not available to examine effects across the whole age range. The effect size increased with increasing duration of follow-up, but this is a marker also for the duration of the intervention since most studies were short term with follow-up assessment at or shortly following the end of the intervention.

Meta regression—Heterogeneity for the outcome VO_2 max was also examined with meta-regression. Covariates defined a priori included trial quality, dose of intervention, duration of intervention and length of follow-up. In univariate analyses, the Jadad score had no effect on the level of VO_2 max achieved at the end of exercise training. Statistically significant associations were seen with dose of intervention, duration of intervention and duration of follow-up. In multivariate analyses both the dose of the intervention and the duration of follow-up contributed to the heterogeneity of VO_2 max, where the weighted mean difference (WMD) for VO_2 max is multiplied by a factor of 1.01 per unit increase in dose (coefficient log WMD 0.0137 95% CI 0.0019 to 0.025 p=0.023), and the weighted mean difference for VO_2 max is multiplied by a factor of 1.03 per week increase in follow-up duration (coefficient log WMD 0.0302 95% CI 0.013, 0.046 p<0.001). Thus the level of VO_2 max at the end of exercise training increases with increasing dose of the intervention, and increasing follow-up period. As noted above, since most studies were short term studies, the follow-up period is a marker for exercise duration, which is also included in the estimate of dose.

Sensitivity analyses—The majority of studies include an aerobic exercise component. To determine the impact of aerobic exercise alone, sensitivity analyses were carried out excluding studies which focused exclusively on resistance training. This had no significant effect on the pooled analysis for the outcomes VO_2 max or distance on the 6 minute walk.

Health related quality of life—The number of different scales used to assess HRQoL, and the different intervention groups (both aerobic and resistance training), as well as the relatively few trials that reported this as an outcome, meant that a pooled analysis was inappropriate. Data has been presented qualitatively in Table 02. Nine of 29 trials reported HRQoL as an outcome. Seven out of nine studies found improvements in HRQoL in the intervention group compared to control. Five studies used the disease specific measure the Minnesota Living with Heart Failure questionnaire (Belardinelli 1999; Parnell 2002; Ponikowski 1997; Teo 1995 EXERT; Tyni-Lenne 2001) where significant improvements were seen for 4/5 studies over the short term. Two of these 5 studies measured quality of life over the longer term of 12 months, one showed improvement was maintained over the long term (Belardinelli 1999), the other showed no difference between intervention and control groups, as for the shorter term assessment (Teo 1995 EXERT). Other scales used included the MOS Short Form (SF) 36, CHF questionnaire, Sickness Impact Profile (SIP) and Nottingham Health Profile (NHP) parts 1 and 2.

DISCUSSION

This is the most comprehensive systematic review to date to examine the effectiveness of exercise training for heart failure. However, the trials identified for inclusion were mostly small and of relatively poor methodological quality, recruiting mostly men, and patients with stable chronic heart failure. Patients with severe disease and co-morbidities were often excluded. The findings therefore are confined to this particular group of patients and may not be generalisable to all patients with heart failure.

Highly statistically significant improvements in exercise capacity were found as assessed by maximum oxygen uptake, exercise duration, distance on the 6 minute walk and physical work capacity. These improvements in intermediate outcomes confirm previous findings (Lloyd-Williams 2002). As most trials are of relatively short duration, it is unclear whether these improvements are sustained. Indeed, conflicting results were found for the two largest trials monitoring the effects of exercise training over 12 months where sustained improvement in functional capacity was found in one trial (Belardinelli 1999), and no effect of exercise training was found in the other (Teo 1995 EXERT).

One of our principal objectives was to determine the effect of exercise training on clinical outcomes. Only one trial with a long follow-up period examined the effect of exercise training on mortality and morbidity, where favorable outcomes were seen for cardiac mortality and hospital readmissions (Belardinelli 1999). The authors of this trial state that the patients who died had a higher resting heart rate, end-diastolic diameter and wall thickening score index, and lower systolic blood pressure and VO₂ max at peak exercise than those patients who survived. Other studies did report clinical events as reasons for loss to follow-up, but the majority of these (7/8 trials) were short term studies. Pooling this data for the 8 of 29 trials reporting all cause mortality showed no evidence of effect of exercise training on this outcome. Further longer term trials are needed to examine the effect of exercise training on clinical outcomes. Several trials are currently underway and we await the results with interest. The Exercise Intervention Strategies in Heart Failure Trial (EXIST) is a multicentre trial designed to examine the effect of exercise training on morbidity and mortality in heart failure patients (NRR ongoing trial 1). The trial was due to be completed in December 2002. Another trial, due to complete in January 2004 looks specifically at elderly patients with heart failure and whether long term provision of exercise training can improve mortality and morbidity (NRR ongoing trial 2).

Whilst it was not our primary aim to examine adverse events, it is noteworthy that only one of 29 trials reported complications associated with training, and in the most severe patients (Jette 1991). As most of the trials are conducted in patients with stable chronic heart failure with NYHA functional class II or III, perhaps this is not unexpected. Concerns about safety have historically been the reason for exclusion of heart failure patients from exercise training and cardiac rehabilitation programmes. Today, it is now generally accepted that exercise training is safe in patients with stable heart failure, but that there is as yet no trial evidence to recommend exercise training in unstable heart failure or those with NYHA class IV (CHF Guidelines 2001). We were unable to examine the effects of exercise training separately for those patients with dilated cardiomyopathy and those with heart failure

secondary to coronary heart disease as most trials recruited a mix of these patients, the majority being those in the latter group. Similarly we were unable to examine the effects of gender or age on outcome. Lack of research evidence in these groups may result in exclusion of women and the elderly from training programmes.

Relatively few trials examined health related quality of life. Of those that used validated scales to assess this, many different instruments were used over different time periods which meant that pooling data statistically was inappropriate. Most of the studies that measured this outcome (7 of 9 studies) showed beneficial effects of exercise training. As for the exercise variables above, the 2 trials which measured quality of life over the long term (12 months) had conflicting results (Belardinelli 1999; Teo 1995 EXERT). More large scale trials of longer duration are needed to resolve these discrepancies. The publication of the two longer term ongoing trials cited above (NRR ongoing trial 1, NRR ongoing trial 2) will add to the existing evidence and may help resolve these issues.

The exercise intervention varied in mode, intensity and duration between studies. The current guidelines for exercise training in heart failure acknowledge the benefits of aerobic training but that the precise protocol is yet to be established and should be individually tailored to baseline clinical and functional status. Relatively little attention has been paid to resistance training, and it is not generally recommended until further data are available (CHF Guidelines 2001). Most of the studies included in this review examined aerobic training. Exclusion of the few studies which focused exclusively on resistance training had no effect on functional outcomes. The outcome VO₂ max was most frequently reported and showed large heterogeneity between studies. To try to explain this and examine the impact of different levels of exercise on VO₂ max, we performed metaregression. The dose of the intervention (the product of exercise duration, number of sessions and duration of training period) explained much of the variation, with improvements in VO₂ max seen for increasing "doses" of exercise training. This finding is important and with the advent of longer term studies, the longer term effects of different training periods can be established.

AUTHORS' CONCLUSIONS

Implications for practice

This review shows that exercise training improves exercise capacity and HRQoL in patients with NYHA functional status class II or III heart failure. However, further work is necessary to inform clinical guideline development. At present exercise training is only recommended in those patients with stable heart failure and NYHA functional class II or III, and only aerobic exercise training is recommended in a supervised hospital based setting, each protocol being tailored to individual needs. Whilst each patient must be treated as an individual, some broad protocols informed by research would help in clinical practice. Due to lack of research there is little evidence of benefit in certain groups (more severe patients, elderly people, women) who may then subsequently be omitted from programmes. The trial evidence to date is unlikely to represent the majority of patients with heart failure.

Implications for research

The findings are based on small trials in patients who are unrepresentative of the total population of patients with heart failure. The effectiveness of exercise training on functional capacity and quality of life is clear in the short term but is unknown in the longer term. Large, long-term pragmatic trials of exercise training are needed to determine the effectiveness of exercise training on morbidity, quality of life, and mortality. The value of continued exercise training for maintenance of benefit also requires evaluation.

Acknowledgments

We would like to acknowledge the following authors for providing us with additional data, A Maiorana, A Gordon.

We would like to acknowledge Dr Andrea Conti and Dr Jan Melichar for translations.

SOURCES OF SUPPORT

Internal sources

- Department of Social Medicine, University of Bristol, UK.
- Department of Public Health and Epidemiology, University of Birmingham, UK.

External sources

British Heart Foundation, UK.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Belardinelli 1992

Methods	Parallel group RCT
Participants	. HF diagnosis mixed, n=12 IHD, n=8 DCM. LVEF<40%. 20 patients randomised, mean age 61.5 years, 90% men
	Aerobic exercise in outpatient setting for 8 weeks, 3 times a week for one hour. Workload was prgressively increased from 40% VO2max to 65% in the last week. Follow-up assessment at end of intervention period of 8 weeks
Outcomes	Exercise duration
Notes	Been translated from Italian publication

Belardinelli 1995

Methods	Parallel group RCT	
Participants	HF diagnosis mixed - $n=18$ IHD, $n=37$ DCM, NYHA class 2 or 3. 55 patients randomised, 85% men, mean age 55 years	
Interventions	Aerobic exercise, 1 hour 3 times a week for 8 weeks on a bike ergometer, intensity altered according to individuals progression, patients monitored by telemetry. Follow-up assessment at 12 months	
Outcomes	VO2max Peak workload	

Notes

Belardinelli 1999

Methods	Parallel group RCT
Participants	HF diagnosis mixed - 85% ischaemic cardiomyopathy, 15% idiopathic DCM, LVEF <40%. 99 patients randomised, 89% men, mean age 59 years
Interventions	Aerobic exercise - 2 phases - 8 week programme and 12 months maintainance programme. Phase 1 - warm up stretching 15-20 minutes, 40 mins on bike ergometer for at 60% VO2max, 5 minutes cool down, 3 times a week. Phase 2 - repeat of phase 1 but 2 times a week for remaining 12 months. Compliance from attendance at sessions -89%. Follow-up measurement at 14 months (repeat exercise test), patients monitored for 3.3 years
Outcomes	VO2max HRQoL
Notes	

Cider 1997

Methods	Parallel group RCT
Participants	Mixed CHF patients, most secondary to IHD. NYHA class 2 or 3, CHF diagnosis for at least a year. 24 patients randomised, 67% men, mean age 63 years
Interventions	Strength/resistance training - peripheral dynamic training (circuit weight training regimen 60% 1 rep maximum), 60 minutes, 2 times a week for 5 months. Compliance 75%. Follow-up assessment at end of intervention at 5 months
Outcomes	HRQoL
Notes	

Coats 1990

Methods	Cross over RCT
Participants	All patients had diagnosis of HF secondary to MI, LVEF<40%. 11 patients randomised, all men, mean age 63 (7.6) years
Interventions	Aerobic exercise on bike ergometer at 70-80% max HR. 1 minute warm up, 20 minutes cycling, 1 minute cool down, 5 days a week for 8 weeks. Exercise performed at home - patients given a HR monitor. Control group asked to avoid exercise over and above their normal level, particularly if it caused breathlessness or fatigue. Following crossover from the trained group, bikes were taken from them and the same activity restriction was recommended. Data has been combined for the 2 arms, but the authors explicitly state there were no carry over effects. Compliance to exercise was monitored by bike revolutions (mean compliance 74%). Followed up at the end of the intervention at 16 weeks
Outcomes	VO2 max Exercise duration
Notes	

Coats 1992

Methods	Cross over RCT
Participants	All patients had diagnosis of HF secondary to MI, LVEF<40%, NYHA class 2 or 3. 19 patients randomised, all men, mean age 61.8 years
Interventions	Aerobic exercise on bike ergometer at 50 rpm for 20mins 5 times a week for 8 weeks. Bikes used at home by the patient - given HR monitor. Compliance from bike revolutions - mean 77.3%. Control group asked to avoid exercise over and above their current level, particularly if it caused dyspnoea. Data combined for the 2 arms of the trial, but the authors explicitly state there were no carry-over effects. Followed up at the end of the intervention at 16 weeks
Outcomes	VO2 max Exercise duration
Notes	

Dubach et al studies

Methods	Parallel group RCT
Participants	CHF secondary to CHD - all patients had had a prior MI, NYHA class 2 or 3, LVEF <40%. 25 patients randomised, all men, mean age 55 years
Interventions	Aerobic exercise - 8 week residential course in Swiss mountains. Comprehensive rehabilitation including exercise, education and a low fat diet. Outdoor walking for 1 hour twice a day, stationary cycling 4 times a week for 45 minutes at 70-80% HR reserve. Follow-up assessment at end of intervention period of 8 weeks
Outcomes	VO2max Exercise time Exercise capacity
Notes	

Gottlieb 1999

Methods	Parallel group RCT
Participants	Mixed CHF - primary n=18, ischaemic n=7, NYHA 2 or 3, LVEF <40%. 33 patients randomised, 88% men, age range 64-67 years
Interventions	Aerobic exercise, 6 months supervised training 3 times a week, cycling and treadmill walking, exercise progressively increased to perceived exertion of 12-13 on the Borg Scale. Compliance 75%. Outcome assessment at end of intervention period of 6 months
Outcomes	VO2 max Exercise duration Distance on 6 minute walk
Notes	

Hambrecht 1995

Methods	Parallel group RCT
Participants	Majority of patients DCM (19/22), remainder IHD. NYHA class 2 or 3, LVEF <40%. 22 patients randomised, all men, mean age 51 years

Rees et al.

Interventions

Aerobic exercise, 3 weeks in hospital, remainder of 6 months at home, and group sessions. Hospital 10 minutes 6 times a day for 3 weeks on a bike ergometer under strict supervision, workload 70%
VO2max. Home - asked to exercise close to target HR (bikes and pulse rate monitoring equipment
loaned to patients) twice a day for 40 minutes, plus also attend 2 group sessions per week for 1 hour
each. Follow-up at end of the intervention period of 6 months

loaned to patients) twice a day for 40 minutes, plus also attend 2 group sessions per week for 1 hour each. Follow-up at end of the intervention period of 6 months

Outcomes

VO2 max

Exercise duration

Notes

Page 16

Hambrecht 1998

Methods	Parallel group RCT
Participants	Mixed CHF - DCM n=13, CHD n=7, NYHA 2 or 3, LVEF<40%. 20 patients randomised, all men, mean age 55 years
Interventions	Aerobic exercise, 3 weeks on an individual care ward and remaining 6 months at home. 3 weeks - bike ergometer 6 times daily for 10 minutes at 70% VO2max. Home - patient took bike ergometer home to exercise 5 times a week for 40 minutes (total of twice daily), and attend 1 group session per week. Compliance to home training estimated to be 70%. Follow-up assessment at end of intervention period of 6 months
Outcomes	VO2max
Notes	

Hambrecht 2000

Methods	Parallel group RCT
Participants	Majority of patients DCM (61/73), remainder IHD. LVEF <40%. 73 patients randomised, all men, mean age 54.5 years
Interventions	Aerobic exercise, 2 weeks on an individual care ward and remaining 6 months at home. 2 weeks - bike ergometer 46 times daily for 10 minutes at 70% VO2max. Home - patient took bike ergometer home to exercise 5 times a week for 20 minutes at 70% VO2max, and attend 1 group session per week of 1 hour duration. Follow-up assessment at end of intervention period of 6 months
Outcomes	VO2 max Exercise duration
Notes	

Jette 1991

Methods	Parallel group RCT
Participants	CHF secondary to MI, NYHA 2 or 3 and LVEF<50%. 39 patients randomised, all men, mean age 50.8 years
Interventions	Aerobic exercise 5 days a week for 4 weeks - jogging 5 mins 3 times a day, cycling 15 mins (both at 70-80% max HR), calisthenics (30 mins) and relaxation training (20 mins). Follow-up assessment at end of intervention period at 4 weeks
Outcomes	VO2max Peak workload
Notes	

Keteyian 1996

Methods	Parallel group RCT
Participants	Mixed CHF - IHD (n=9) and DCM (n=20) CHF patients, NYHA 2 or 3, LVEF 35% or less. All men, mean age 54 years
Interventions	Aerobic exercise, 45 minutes (5 mins warm up, 35 mins 3 types aerobic activity, 5 mins cool down) 3 times a week for 24 weeks. Follow-up measurements at 24 weeks
Outcomes	VO2max Exercise duration
Notes	

Kiilavuori 1996

Methods	Parallel group RCT
Participants	Mixed CHF - CHD (n=9) and DCM (n=18), NYHA 2 or 3, LVEF<40%. 27 patients randomised, 96% men, mean age 52 years
Interventions	Aerobic exercise - 3 months supervised, 3 months home based. Supervised - bike ergometer 30 mins 3 times a week at 50-60% VO2max for 2-3 weeks, then increased workload depending on individual HR thereafter. Home based - walking, rowing, cycling or swimming depending on individual instruction. Control group advised not to change their previous physical activity during the 6 months. Follow-up assessment at 6 months
Outcomes	VO2max Exercise duration
Notes	

Maiorana 2000

Methods	Cross over RCT
Participants	Mixed CHF, n=7 CHD, n=6 DCM, NYHA 1-3, LVEF mean 26%. 13 patients randomised, all men, mean age 60 years
Interventions	Aerobic and resistance training. 8 weeks training, 1 hour 3 times a week. Whole body exercise concentrating on the large muscle groups. Combination of circuit training, cycle ergometry, treadmill and resistance weight training. Intensity and duration of exercise gradually increased over the 8 week period. Follow-up assessment at 16 weeks (cross over trial)
Outcomes	VO2max Exercise duration
Notes	

Meyer 1996

Methods	Cross over RCT
Participants	Severe CHF, patients are hospitalised. Mix of CHF due to DCM (n=9) and IHD (n=9). 18 patients randomised, all men, mean age 52 years
Interventions	Aerobic and resistance training. 3 weeks in hospital training on bike ergometer and treadmill at 50% max work rate, 10-15 minutes 3-5 times per week for each exercise respectively. Also muscle strength

	exercises, coordination and inspiratory muscle training 3 times a week for 20 minutes. Follow up after 6 week intervention period. Data presented combined for the 2 arms, but authors explicitly state that no evidence of carry-over effects was found
Outcomes	VO2 max Peak workload (Watts)
Notes	

Oka 2000

Methods	Parallel group RCT
Participants	Mixed CHF, LVEF <40%. 40 patients randomised, 77.5% men, age range 30-76 years
Interventions	Aerobic and resistance training at home for 3 months. Walking at home 3 times a week increasing the intensity and duration over the initial 2-3 weeks to 70% peak HR for 40-60 minutes. Total body unilateral resistance exercises 2 times a week up to 75% 1 rep max. Weekly phonecalls to answer questions and monitor adherence. Follow-up assessment at end of intervention period of 3 months
Outcomes	VO2max Exercise duration HRQoL
Notes	

Owen 2000

Methods	Cross over RCT
Participants	Mixed aetiology of CHF, 67% CHD, 33% AF, LVEF<40%. Focus on the elderly >75 years, mean age 81 years, 75% men. 22 patients randomised
Interventions	Resistance training - 6 station circuit with stations alternating between stamina and strengthening exercises. Patients worked in a range comfortable to them and warned not to exceed 70% max HR (showed how to monitor this). Average session 1 hour, once a week for 12 weeks. Follow-up assessment at end of intervention period at 24 weeks (cross over trial)
Outcomes	Distance on 6 min walk
Notes	

Parnell 2002

Methods	Parallel group RCT
Participants	Mixed aetiology of CHF, NYHA 2 or 3. 21 patients randomised, 91% men, age range 53-57 years
Interventions	Aerobic exercise - 8 weeks of walking, cycling and light weights at 50-60% maximum HR, increasing exercise duration progressively from 30 mins-60 mins per day for 5-7 days per week. Follow-up assessment at end of intervention period of 8 weeks
Outcomes	Distance on 6 min walk HRQoL
Notes	

Ponikowski 1997

Methods	Parallel group RCT
Participants	Mixed aetiology of CHF, most (88%) CHD, 12% DCM, LVEF <45%. 32 patients randomised, 81% men, mean age 57 years
Interventions	Aerobic exercise training - first 1-2 weeks in hospital, following modified Royal Canadian Airforce Training programme, and graded walking, under the supervision of a physiotherapist (max HR 75-80%). 35-45 mins exercise per day. For remaining 16 weeks, similar walking programme to be done individually at home for 6 days each week. Comparison group - usual care. Follow-up assessment at end of 16 weeks
Outcomes	VO2max Exercise duration Peak workload (Watts) Clinical outcomes. HRQoL
Notes	Been translated from Polish publication

Pu 2001


Methods	Parallel group RCT
Wicthous	Taranet group Re 1
Participants	Mixed group of mild-moderate CHF, ischaemic and idiopathic, NYHA class 1-3. All women over the age of 65 years (mean 77 years), 16 patients randomised
Interventions	Resistance training - high intensity progressive training 3 times a week for 10 weeks, 1 hour sessions. Dynamic contraction of large upper and lower body groups, at 80% weight that could be lifted in good form (1 repetition max). Control group received "placebo" controlled stretching. Attendance at classes averaged 98% in both groups. Follow-up assessment at end of intervention period of 10 weeks
Outcomes	VO2max Distance on 6 min walk
Notes	

Quittan 1999

Methods	Parallel group RCT
Participants	All DCM patients, NYHA 2 or 3, LVEF <30%. 25 patients randomised, 81.5% men, mean age 55.3 years
Interventions	Aerobic exercise programme - 3 months bike ergometer training and step exercises 1 hour (short warm up and cool down and 2 times 25 minutes training) 2-3 times per week, at 50% maximal functional capacity. Follow up assessment at end of intervention period of 3 months
Outcomes	VO2max Exercise duration HRQoL
Notes	

Teo 1995 EXERT

Methods	Parallel group RCT
Participants	Mixed CHF, for majority of patients CHD (76%), NYHA 1-3, LVEF >40%. 181 patients randomised, 81% men, mean age 65.5 years



Page 20

Outcomes Distance on 6 min walk HRQoL

Notes

Rees et al.

Tyni-Lenne 1997

Methods	Cross over RCT
Participants	Aetiology of CHF both CHD (n=8) and DCM (n=8). NYHA class 2 or 3, LVEF<40%. 16 patients randomised - all women, mean age 62 years
Interventions	Endurance training of leg muscles 3 times a week for 8 weeks on a modified knee extensor ergometer. 15 minutes at 60 reps per minutes intensity progressively increasing from 65-75% peak work rate. Follow-up at the end of 16 weeks (crossover study)
Outcomes	VO2 max Distance on 6 minute walk
Notes	Contacted authors re: QoL data

Tyni-Lenne 2001

Methods	Parallel group RCT
Participants	Aetiology of CHF both CHD and DCM. LVEF<40% and NYHA class 2 or 3. 24 patients randomised, 54% men, mean age 62.5 years. Randomisation to intervention 2:1
Interventions	Strength/resistance exercise using resistance rubber bands. 8 weeks supervised group exercise 3 times a week for 1 hour. 6 minutes warm up, 45 minutes training - continuous repetitive contractions against a resistance - one muscle group at a time with 25 reps, 9 minutes cool down. Compliance measured as attendance - 95%. Follow-up assessment at the end of the 8 week intervention period
Outcomes	VO2 max Distance on 6 minute walk HRQoL
Notes	

Tyni-Lenne/Gordon 96

Methods	Parallel group RCT				
Participants	Aetiology of CHF both CHD and DCM. NYHA class 2 or 3. 21 patients randomised, all men, mear 60 years				
Interventions	Endurance training with continuous knee extensor exercises at 60 reps per minute performed on a modified bike ergometer. Two intervention groups - 1 legged exercise and 2 legged exercise where the same relative quantity of muscle work per session was performed, but the quantity of muscle mass activated was different. 8 weeks of training 3 times a week for 25-40 minutes. Compliance estimated to be between 90-100%. Follow-up assessment at the end of the intervention period at 8 weeks				
Outcomes	Distance on 6 minute walk HRQoL VO2max (Gordon 96)				

Notes	Assuming same study as Gordon 1996. VO2max measured in that study	

Wielenga 1998

Methods	Parallel group RCT
Participants	Aetiology of CHF both CHD and DCM. LVEF <40% and NYHA class 2 or 3. 67 patients randomised, all men, mean age 64 years. Patients stratified and outcomes expressed in terms of those greater and less than 65 years of age
Interventions	Aerobic exercise training - 12 weeks training 3 times a week - 45 minute sessions of walking, cycling and ball games 10 mins each with 5 mins rest. Target HR maintained for at least 20 minutes. Follow-up assessment at end of intervention period of 12 weeks
Outcomes	VO2max Exercise duration
Notes	

Wielenga 1999 CHANGE

Methods	Parallel group RCT
Participants	Aetiology of CHF both CHD and DCM. LVEF <40% and NYHA class 2 or 3. 80 patients randomised, all men, mean age 56.6 years
Interventions	Aerobic exercise, 12 weeks training 3 times a week, comprising 3 exercises for 10 mins each separated by 5 mins rest (cycling, walking and ball games), at 60% max HR. Walking progressed to slow running during the course of the training period. 85.4% compliance. Follow-up assessment at end of the intervention period of 12 weeks
Outcomes	VO2max Exercise duration
Notes	

Willenheimer 1998

Methods	Parallel group RCT
Participants	Aetiology of CHF both CHD (75%) and DCM. Boston HF criteria and LVEF <45%. 54 patients randomised, 71.5% men, mean age 64 years
Interventions	Aerobic exercise - 16 weeks interval training on a bike ergometer - 90 seconds exercise at 80% VO2 max, 30 seconds rest. Exercise time gradually increased from 15 minutes total 2 times a week to 45 minutes 3 times a week from week 7. Mean compliance 74.5%. Follow-up assessment at end of intervention period of 16 weeks
Outcomes	VO2max Peak workload (Watts)
Notes	

AF: atrial fibrillation
CHF: chronic heart failure
CHD: coronary heart disease
DCM: dilated cardiomyopathy

HR: heart rate

HRQoL: health related quality of life LVEF: left ventricular ejection fraction

Mins: minutes

NYHA: New York Heart Association classification

QoL: quality of life

RCT : randomised controlled trial VO2max: peak oxygen uptake

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion		
Adamopoulos 1995	No relevant outcomes		
Barnard 2000	No relevant outcomes		
Belardinelli2 1995	Not an RCT		
Cohen-Solal 1994	Not an RCT		
Davey 1992	As stated in Coats 1992, there is overlap in some of the patients taking part in each trial. Efforts have been made to obtain data for those that participated only in the Davey trial but these studies were conducted over 10 years ago. To be conservative we have excluded this study from the analyses		
Gordon 1999	Exercise versus exercise comparison - not usual care		
Johnson 1998	Inspiratory muscle training, not whole body training		
Kavanagh 1996	Not an RCT		
Koch 1992	Only relevant outcome was QoL with little detail given in the paper. Written to the authors for the data available but no response		
Metra 1998	Not an RCT		
Page 1994	Exercise versus exercise comparison - not usual care		
Taylor 1999	No baseline data were presented in the publication for the outcomes of interest. Written to authors to try to obtain these, but no response		
Tokmakova 1999	No data were presented for the control group in the publication. Written to authors to try to obtain these, but no response		
Tyni-Lenne 1998	Not an RCT		
Tyni-Lenne 1999	Patients were previously trained		

DATA AND ANALYSES

Comparison 1 All exercise interventions versus usual care

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Cardiac mortality	1	99	Odds Ratio (M-H, Fixed, 95% CI)	0.32 [0.13, 0.80]
2 Non-fatal Myocardial Infarction	1	99	Odds Ratio (M-H, Fixed, 95% CI)	0.48 [0.04, 5.47]
3 Hospital readmission for Heart Failure	1	99	Odds Ratio (M-H, Fixed, 95% CI)	0.28 [0.09, 0.85]
4 Deaths not associated with training but	9	483	Odds Ratio (M-H, Fixed, 95% CI)	1.12 [0.58, 2.15]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
reported reasons for loss to follow-up				
5 VO2 max (ml/kg/min)	24	848	Mean Difference (IV, Random, 95% CI)	-2.16 [-2.82, -1.49]
6 Exercise duration (mins)	15	510	Mean Difference (IV, Fixed, 95% CI)	-2.38 [-2.85, -1.92]
7 Maximum work capacity (Watts)	6	219	Mean Difference (IV, Fixed, 95% CI)	-15.13 [-17.67, -12. 59] 59]
8 Distance on 6 minute walk (meters)	8	282	Mean Difference (IV, Random, 95% CI)	-40.87 [-64.65, -17. 10]

Comparison 2 Subgroup analyses

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 VO2 max (ml/kg/min)	24	4191	Mean Difference (IV, Random, 95% CI)	-2.19[-2.48,-1.90]
1.1 "Dose" of intervention =/> 30 units	11	432	Mean Difference (IV, Random, 95% CI)	-2.78[-3.88,-1.69]
1.2 "Dose" of intervention < 30 units	13	416	Mean Difference (IV, Random, 95% CI)	-1.64[-2.15,-1.12]
1.3 Jadad score = 3 and above	7	341	Mean Difference (IV, Random, 95% CI)	-2.01[-2.90,-1.12]
1.4 Jadad score = 2 and below	15	458	Mean Difference (IV, Random, 95% CI)	-2.28[-3.47,-1.10]
1.5 Duration of intervention >12 weeks	10	420	Mean Difference (IV, Random, 95% CI)	-2.62[-3.76,-1.48]
1.6 Duration of intervention =/<12 weeks	14	428	Mean Difference (IV, Random, 95% CI)	-1.79[-2.33,-1.24]
1.7 Mean age > 55 years	15	540	Mean Difference (IV, Random, 95% CI)	-1.77[-2.50,-1.03]
1.8 Mean age =/< 55 years	9	308	Mean Difference (IV, Random, 95% CI)	-2.95[-4.25,-1.64]
1.9 Duration of follow up > 16 weeks	9	397	Mean Difference (IV, Random, 95% CI)	-2.74[-3.83,-1.65]
1.10 Duration of follow up =/< 16 weeks	15	451	Mean Difference (IV, Random, 95% CI)	-1.55[-2.17,-0.94]

Analysis 1.1 Comparison 1 All exercise interventions versus usual care, Outcome 1 Cardiac mortality

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 1 All cause mortality up to 12 month follow up




Analysis 1.2 Comparison 1 All exercise interventions versus usual care, Outcome 2 Non-fatal Myocardial Infarction

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 2 All cause mortality more than 12 months follow up

Study or subgroup	Experimental n/N	Control n/N	Odds Ratio M-H,Fixed,95% CI	Weight	Odds Ratio M-H,Fixed,95% C
Austin 2005	31/85	38/94	+	10.8 %	0.85 [0.46, 1.55
Belardinelli 1999	9/50	20/49	-	7.8 %	0.32 [0.13, 0.80
HF ACTION 2009	189/1159	198/1171	•	77.8 %	0.96 [0.77, 1.19
Mueller 2007	9/25	12/25		3.6 %	0.61 [0.20, 1.89
Total (95% CI) Total events: 238 (Experim Heterogeneity: Chi ² = 5.69 Test for overall effect: Z =	$P_{1}, df = 3 (P = 0.13); I^{2} = 0.13$	1339	•	100.0 %	0.88 [0.73, 1.07]
			0.01 0.1 I IO 100 Favours experimental Favours control		

Analysis 1.3 Comparison 1 All exercise interventions versus usual care, Outcome 3 Hospital readmission for Heart Failure

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 3 Hospital admission up to 12 month follow up



Analysis 1.4 Comparison 1 All exercise interventions versus usual care, Outcome 4 Deaths not associated with training but reported reasons for loss to follow-up


Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 4 Hospital admission more than 12 months follow up

Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% Cl
Austin 2005	28/85	33/94	+	3.9 %	0.94 [0.62, 1.41]
Belardinelli 1999	5/50	14/49		1.8 %	0.35 [0.14, 0.90]
HF ACTION 2009	729/1159	760/1171	•	94.0 %	0.97 [0.91, 1.03]
Mueller 2007	2/25	3/25		0.4 %	0.67 [0.12, 3.65]
Total (95% CI) Total events: 764 (Treatmer Heterogeneity: Chi ² = 4.74 Test for overall effect: Z =	, $df = 3 (P = 0.19); I^2$	1339 =37%		100.0 %	0.96 [0.90, 1.02]
			0.01 0.1 1 10 100 Favours exercise Favours control		

Analysis 1.5 Comparison 1 All exercise interventions versus usual care, Outcome 5 VO2 max (ml/kg/min)

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care

Outcome: 5 Hospital admission heart failure only



Analysis 1.6 Comparison 1 All exercise interventions versus usual care, Outcome 6 Exercise duration(mins)

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 6 Health related quality of life - MLWHF

Study or subgroup	Treatment		Control		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	1000	IV,Random,95% CI
Austin 2005	95	22.9 (14.7)	94	36.9 (21.3)		20.0 %	-14.00 [-19.22, -8.78]
Belardinelli 1999	48	39 (20)	46	52 (20)		16.1 %	-13.00 [-21.09, -4.91]
Dracup 2007	87	35.7 (23.7)	86	43.2 (26.5)		16.9 %	-7.50 [-14.99, -0.01]
Koukouvou 2004	16	34.1 (13)	19	45.2 (9)		16.8 %	-11.10 [-18.65, -3.55]
McKelvie 2002	57	-3.4 (18.1)	67	-3.3 (13.9)		19.3 %	-0.10 [-5.86, 5.66]
Passino 2006	44	32 (26.5)	41	53 (32)	-	10.9 %	-21.00 [-33.54, -8.46]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2			353 = 0.004); ² =	=71%	-	100.0 %	-10.33 [-15.89, -4.77]
rest for overall effect. 2		2,00027)					
					-20 -10 0 10 2 ours expercise Favours cont		

Analysis 1.7 Comparison 1 All exercise interventions versus usual care, Outcome 7 Maximum work capacity (Watts)

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 7 Health related quality of life - all scales

Austin 2005 95 22.9 (14.7) 94 36.9 (21.3) ★ 13.1% -0.76 [-1.06. Belardinelli 1999 48 39 (20) 46 52 (20) ★ 11.2% -0.64 [-1.06. Dracup 2007 87 35.7 (23.7) 86 43.2 (26.5) ★ 13.0% -0.30 [-0.66. HF ACTION 2009 1159 -5.21 (13.72) 1171 -3.28 (13.97) ★ 15.6% -0.14 [-0.22. Klocek 2005 (High) 14 -109 (23.5) 7 -7.17 (23.5) ★ 44.4% -1.52 [-2.57. Koukouvou 2004 16 34.1 (13) 19 45.2 (9) ★ 7.2% -0.99 [-1.69. McKelvie 2002 57 -3.4 (18.1) 67 -3.3 (13.9) ★ 12.2% -0.01 [-0.36.	udy or subgroup 7	Treatment		Control		Std. Mean Difference	Weight	Sto Mea Difference
Belardinelli 1999 48 39 (20) 46 52 (20) → 112 % -0.64 [-1.06 Dracup 2007 87 357 (23.7) 86 43.2 (26.5) → 13.0 % -0.30 [-0.66 HF ACTION 2009 1159 -5.21 (13.72) 1171 -3.28 (13.97) → 15.6 % -0.14 [-0.22 Klocek 2005 (High) 14 -109 (23.5) 7 -7.17 (23.5) → 44.4 % -1.52 [-25.7 Koukouvou 2004 16 34.1 (13) 19 45.2 (9) → 7.2 % -0.99 [-1.69 McKehie 2002 57 -3.4 (18.1) 67 -3.3 (13.9) → 12.2 % -0.01 [-0.36		Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
Dracup 2007 87 357 (23.7) 86 43.2 (26.5) ■ 112.%0.61 [-1.06. Dracup 2007 87 35.7 (23.7) 86 43.2 (26.5) ■ 13.0	ustin 2005	95	22.9 (14.7)	94	36.9 (21.3)	•	13.1 %	-0.76 [-1.06, -0.47
HF ACTION 2009 1159 -5.21 (13.72) 1171 -3.28 (13.97) ■ 15.6% -0.14 [-0.22] Rlocek 2005 (High) 14 -109 (23.5) 7 -7.17 (23.5) — 44.4% -1.52 [-2.57] Rlocek 2005 (Low) 14 -99 (23.5) 7 -7.17 (23.5) — 48.8% -1.12 [-2.10] Koukouvou 2004 16 34.1 (13) 19 45.2 (9) — 72.% -0.99 [-1.69] McKehke 2002 57 -3.4 (18.1) 67 -3.3 (13.9) ■ 12.2% -0.01 [-0.38]	elardinelli 1999	48	39 (20)	46	52 (20)	•	11.2 %	-0.64 [-1.06, -0.23
Klocek 2005 (High) 14 -109 (23.5) 7 -71.7 (23.5)	racup 2007	87	35.7 (23.7)	86	43.2 (26.5)	•	13.0 %	-0.30 [-0.60, 0.00
Klocek 2005 (Low) 14 -99 (23.5) 7 -7.1.7 (23.5)	IF ACTION 2009	1159	-5.21 (13.72)	1171	-3.28 (13.97)	•	15.6 %	-0.14 [-0.22, -0.06
Koukouvou 2004 16 34.1 (13) 19 45.2 (9) → 7.2 % -0.99 [-1.69, McKelvie 2002 McKelvie 2002 57 -3.4 (18.1) 67 -3.3 (13.9) + 12.2 % -0.01 [-0.36]	locek 2005 (High)	14	-109 (23.5)	7	-71.7 (23.5)		4.4 %	-1.52 [-2.57, -0.48
McKelvie 2002 57 -3.4 (18.1) 67 -3.3 (13.9) 12.2 % -0.01 [-0.36	locek 2005 (Low)	14	-99 (23.5)	7	-71.7 (23.5)		4.8 %	-1.12 [-2.10, -0.13
	oukouvou 2004	16	34.1 (13)	19	45.2 (9)	-	7.2 %	-0.99 [-1.69, -0.28
Passino 2006 44 32 (26.5) 41 53 (32) - 10.8 % -0.71 [-1.15.	1cKelvie 2002	57	-3.4 (18.1)	67	-3.3 (13.9)	+	12.2 %	-0.01 [-0.36, 0.35
	assino 2006	44	32 (26.5)	41	53 (32)	-	10.8 %	-0.71 [-1.15, -0.27
Willenheimer 2000 20 -0.7 (0.8) 17 0 (1) 7.6 % -0.76 [-1.44,	Villenheimer 2000	20	-0.7 (0.8)	17	0 (1)		7.6 %	-0.76 [-1.44, -0.09
Total (95% CI) 1554 1555 ◆ 100.0 % -0.56 [-0.82, -1	al (95% CI)	1554		1555		•	100.0 %	-0.56 [-0.82, -0.30
leterogeneity: $Tau^2 = 0.11$; $Chi^2 = 43.25$, $df = 9$ (P<0.00001); $i^2 = 79\%$	erogeneity: Tau ² = 0.11	; $Chi^2 = 43$.	25, df = 9 (P<0.0	0001); 12 =7	19%			
est for overall effect: Z = 4.27 (P = 0.000020)	for overall effect: $Z = 4$	4.27 (P = 0.0	000020)					

Analysis 1.8 Comparison 1 All exercise interventions versus usual care, Outcome 8 Distance on 6 minute walk (meters)

Review: Exercise based rehabilitation for heart failure Comparison: 1 All exercise interventions versus usual care Outcome: 8 Distance on 6 minute walk (meters)

Study or subgroup	Treatment N	Mean(SD)	Control	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mear Difference IV.Random,95% C
Gottlieb 1999	11	-44.8 (59.2)	14	-18.6 (40.9)	17,14110011,7376 CI	13.1 %	-26.20 [-67.22, 14.82]
					_		
Owen 2000	15	-21.7 (42)	9	18.4 (31)		16.1 %	-40.10 [-69.46, -10.74]
Parnell 2002	11	-73 (30.5)	10	-2 (25.3)	-	17.6 %	-71.00 [-94.89, -47.11]
Pu 2001	9	-49 (139)	7	3 (97)	•	3.5 %	-52.00 [-167.80, 63.80
Teo 1995 EXERT	64	-17 (64)	78	-20 (78)	-	17.8 %	3.00 [-20.36, 26.36
Tyni-Lenne 1997	8	-37 (78.8)	8	2 (64)		7.5 %	-39.00 [-109.35, 31.35
Tyni-Lenne 2001	16	-55 (61.6)	8	0 (30)		14.2 %	-55.00 [-91.65, -18.35
Tyni-Lenne/Gordon 96	7	-56 (38.4)	7	7 (61.4)		10.2 %	-63.00 [-116.65, -9.35
Total (95% CI)	141		141		•	100.0 %	-40.87 [-64.65, -17.10
Heterogeneity: Tau ² = 687.	.04; Chi ² = 21	.22, df = 7 (P =	0.003); 12 =	=67%			
Test for overall effect: $Z = 1$	3.37 (P = 0.00	075)					
					100 -50 0 50	100	
				Favo	urs treatment Favours co	ntrol	

Analysis 2.1 Comparison 2 Subgroup analyses, Outcome 1 VO2 max (ml/kg/min)

Review: Exercise based rehabilitation for heart failure

Comparison: 2 Subgroup analyses Outcome: 1 VO2 max (ml/kg/min)

Study or subgroup	Treatment		Control		Mean Difference	Weight	Mean Difference
, , ,	N	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I "Dose" of intervention =/	> 30 units						
Belardinelli 1999	48	-4.2 (1.55)	46	-0.8 (2)	+	1.6 %	-3.40 [-4.13, -2.67]
Dubach et al studies	12	-5.7 (4)	13	-1 (4.1)		0.6 %	-4.70 [-7.88, -1.52]
Gottlieb 1999	11	-2.4 (2.8)	14	-0.1 (2.6)		0.9 %	-2.30 [-4.44, -0.16]
Hambrecht 1995	9	-5.8 (3.6)	9	0 (2.7)		0.6 %	-5.80 [-8.74, -2.86]
Hambrecht 1998	9	-4.7 (1.17)	9	0.7 (1.48)	-	1.3 %	-5.40 [-6.63, -4.17]
Hambrecht 2000	31	-1.26 (4.3)	33	-0.3 (4.3)		0.9 %	-0.96 [-3.07, 1.15]
Keteyian 1996	15	-2.5 (2.3)	14	-0.5 (1.87)		1.2 %	-2.00 [-3.52, -0.48]
Kiilavuori 1996	12	-2.4 (7.3)	15	0.1 (5.4)		0.3 %	-2.50 [-7.45, 2.45]
Oka 2000	18	-0.52 (4.27)	18	0 (3.8)	-	0.7 %	-0.52 [-3.16, 2.12]
Ponikowski 1997	16	-2 (3.8)	13	0.5 (4)		0.7 %	-2.50 [-5.36, 0.36]
Wielenga 1998	35	-1.44 (3.05)	32	-0.63 (3)	-	1.2 %	-0.81 [-2.26, 0.64]
Subtotal (95% CI)	216		216		•	10.0 %	-2.78 [-3.88, -1.69]
Heterogeneity: Tau ² = 2.17;	$Chi^2 = 38.21$, d	f = 10 (P = 0.000	003); 12 = 74	1%			
Test for overall effect: $Z = 4$.97 (P < 0.0000	1)					
2 "Dose" of intervention <	30 units						
Belardinelli 1995	36	-1.15 (1.36)	19	0.8 (1.54)	-	1.5 %	-1.95 [-2.77, -1.13]
Coats 1990	10	-3.2 (3.8)	10	-0.8 (3.5)		0.6 %	-2.40 [-5.60, 0.80]
Coats 1992	17	-2.4 (4.5)	17	0 (4.3)		0.6 %	-2.40 [-5.36, 0.56]
Jette 1991	18	-1.52 (3.6)	18	0.1 (3.43)		0.8 %	-1.62 [-3.92, 0.68]
Maiorana 2000	13	-2.6 (4.6)	13	-0.1 (4.14)		0.5 %	-2.50 [-5.86, 0.86]
Meyer 1996	18	-2.4 (7)	18	-0.4 (0.7)		0.6 %	-2.00 [-5.25, 1.25]
Pu 2001	9	0.42 (4.1)	7	-0.35 (2.74)		0.5 %	0.77 [-2.59, 4.13]
Quittan 1999	Ш	-2.6 (3)	12	-0.7 (2.95)		0.8 %	-1.90 [-4.33, 0.53]
Tyni-Lenne 1997	8	-2 (2.35)	8	0.1 (1.8)		0.9 %	-2.10 [-4.15, -0.05]
Tyni-Lenne 2001	16	-1.1 (4.24)	8	1.6 (3.45)		0.6 %	-2.70 [-5.87, 0.47]

	7	-0.5 (2.83)	7	0.3 (4.6)		0.4 %	
Tyni-Lenne/Gordon 96	/					0.4 75	-0.80 [-4.80, 3.20]
Wielenga 1999 CHANGE	35	-1.4 (2.95)	32	-0.6 (3.4)	-+	1.2 %	-0.80 [-2.33, 0.73]
Willenheimer 1998	22	-0.9 (2.6)	27	0.1 (1.9)	-	1.3 %	-1.00 [-2.30, 0.30]
ubtotal (95% CI)	220		196		•	10.4 %	-1.64 [-2.15, -1.12]
eterogeneity: $Tau^2 = 0.0$; $Chi^2 =$ st for overall effect: $Z = 6.19$ (P			=0.0%				
Jadad score = 3 and above Belardinelli 1995	36	-1.15 (1.36)	19	0.8 (1.54)	+	1.5 %	-1.95 [-2.77, -1.13]
Belardinelli 1999	48	-4.2 (1.55)	46	-0.8 (2)	+	1.6 %	-3.40 [-4.13, -2.67]
Coats 1990	10	-3.2 (3.8)	10	-0.8 (3.5)		0.6 %	-2.40 [-5.60, 0.80]
Hambrecht 2000	31	-1.26 (4.3)	33	-0.3 (4.3)		0.9 %	-0.96 [-3.07, 1.15]
Jette 1991	18	-1.52 (3.6)	18	0.1 (3.43)		0.8 %	-1.62 [-3.92, 0.68]
Quittan 1999	11	-2.6 (3)	12	-0.7 (2.95)		0.8 %	-1.90 [-4.33, 0.53]
Willenheimer 1998	22	-0.9 (2.6)	27	0.1 (1.9)	4	1.3 %	-1.00 [-2.30, 0.30]
ubtotal (95% CI)	176	-0.7 (2.6)	165	0.1 (1.2)		7.5 %	-2.01 [-2.90, -1.12]
terogeneity: Tau ² = 0.73; Chi ² : t for overall effect: Z = 4.42 (P idad score = 2 and below	= 15.27, df					75 %	2101 [-2170, -1112]
Coats 1992	17	-2.4 (4.5)	17	0 (4.3)		0.6 %	-2.40 [-5.36, 0.56]
Dubach et al studies	12	-5.7 (4)	13	-1 (4.1)		0.6 %	-4.70 [-7.88, -1.52]
Hambrecht 1995	9	-5.8 (3.6)	9	0 (2.7)		0.6 %	-5.80 [-8.74, -2.86]
Hambrecht 1998	9	-4.7 (1.17)	9	0.7 (1.48)		1.3 %	-5.40 [-6.63, -4.17]
Kiilavuori 1996	12	-2.4 (7.3)	15	0.1 (5.4)		0.3 %	-2.50 [-7.45, 2.45]
Maiorana 2000	13	-2.6 (4.6)	13	-0.1 (4.14)		0.5 %	-2.50 [-5.86, 0.86]
Meyer 1996	18	-2.4 (7)	18	-0.4 (0.7)		0.6 %	-2.00 [-5.25, 1.25]
Oka 2000	18	-0.52 (4.27)	18	0 (3.8)		0.7 %	-0.52 [-3.16, 2.12]
Ponikowski 1997	16	-2 (3.8)	13	0.5 (4)		0.7 %	-2.50 [-5.36, 0.36]
Pu 2001	9	0.42 (3)	12	-0.7 (2.95)		0.7 %	1.12 [-1.45, 3.69]
Tyni-Lenne 1997	8	-2 (2.35)	8	0.1 (1.8)		0.9 %	-2.10 [-4.15, -0.05]
7,	16	-1.1 (4.24)	8	1.6 (3.45)		0.6 %	-2.70 [-5.87, 0.47]
Tyni-Lenne 2001			-	()			-0.80 [-4.80, 3.20]
		-05 (2.83)	7	03 (46)		0.4 %	
Tyni-Lenne/Gordon 96	7	-0.5 (2.83) -1.44 (3.05)	7	0.3 (4.6)		0.4 %	
	7 35 35 234	-1.44 (3.05) -1.4 (2.95)	32 32 224	-0.63 (3) -0.6 (3.4)	•	0.4% 1.2% 1.2%	-0.80 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10]
Tyni-Lenne/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau ² = 3.49; Chi ² Test for overall effect Z = 3.79	7 35 35 35 234 2 = 48.60, d P = 0.00015	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000)	32 32 224	-0.63 (3) -0.6 (3.4)	•	1.2 %	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73]
Tyni-Lenne/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau ² = 3.49; Chi ² fest for overall effect: Z = 3.79	7 35 35 35 234 2 = 48.60, d P = 0.00015	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000)	32 32 224	-0.63 (3) -0.6 (3.4)	•	1.2 %	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73]
Tyni-lenne/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI)	7 35 35 234 2 = 48.60, d P = 0.00015 weeks	-1.44 (3.05) -1.4 (2.95) of = 14 (P = 0.000)	32 32 224 01); I ² =71	-0.63 (3) -0.6 (3.4)	•	12%	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10]
Tyni-Lenner(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subrotal (95% CI) Heterogeneity: Tau ² = 3.49, Chi ² test for overall effect Z = 3.79 Louraion of intervention > 12 \ Belardnelli 1999	7 35 35 35 234 8 = 48.60, d P = 0.00019 weeks 48	-1.44 (3.05) -1.4 (2.95) of = 14 (P = 0.000 5) -4.2 (1.55)	32 32 224 01); ² =7	-0.63 (3) -0.6 (3.4) %		12 % 12 % 11.0 %	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10]
Tyni-Lenne(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau ² = 3.49, Chi ² test for overall effect Z = 3.79 (burdion of intervention > 12.1 Belardinelli 1999 Gottlieb 1999	7 35 35 35 234 2 = 48.60, d P = 0.00018 weeks 48	-1.44 (3.05) -1.4 (2.95) of = 14 (P = 0.000 of = 14 (1.55) -24 (2.8)	32 32 224 01); i ² =71 46	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6)		12 % 12 % 11.0 %	-0.81 [-226.064] -0.80 [-2.33.073] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16]
Tyni-Lenne(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau ² = 3.49; Chri est for overall effect tZ = 3.79 Duration of intervention >12 \times 12 \tim	7 35 35 35 234 8 = 48.60, d P = 0.00019 weeks 48 11	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6)	32 32 224 01); ² =71 46 14	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7)		1.2 % 12 % 11.0 % 16 % 0.9 % 0.6 %	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86]
Fini-Lenne(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) leterogeneity: Tau² = 349; Chi² est for overall effect Z² = 379 Duration of intervention >12 \times 12 \times	7 35 35 35 234 2 = 48.60, d 0 P = 0.00018 weeks 48 11 9 9	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000) 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -4.7 (1.17)	32 32 224 01); i ² =71 46 14 9	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48)	-	12 % 12 % 11.0 % 16 % 09 % 06 % 1.3 %	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17]
Tyni-Lenner(Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity Tau ² = 349, Chi Test for overall effect Z = 3.79 (5 Duration of intervention >12 \times Belardneili 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 1998 Hambrecht 2000	7 35 35 35 234 2 = 48.60, d P = 0.00015 weeks 48 11 9 9 31	-1.44 (3.05) -1.4 (2.95) of = 14 (P = 0.000 of) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3)	32 32 224 01); ² =7 46 4	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3)	-	1.2 % 1.0 % 11.0 % 1.6 % 0.9 % 0.6 % 1.3 % 0.9 %	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15]
Tyni-Lenner(Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau² = 349, Chi Test for overall effect Z = 3.79 (5 Duration of intervention >12 × Belardnell 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 2000 Keteylan 1996	7 35 35 234 2 = 48.60, d P = 0.00015 weeks 48 11 9 9 31	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3)	32 32 224 01); ² =7 46 14 9 9 33	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87)		12% 11.0% 16% 09% 06% 1.3%	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48]
Tyni-Lenner(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity Tau ² = 3.49, Civi Duration of intervention >12 × Belardneil 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 2000 Keteyian 1996 Killavuori 1996	7 35 35 35 234 2 = 48.60, d P = 0.0001! weeks 48 11 9 9 31 15	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -47 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3)	32 32 224 01); ² =71 46 14 9 9 33 14	-0.63 (3) -0.6 (3.4) % % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4)		12% 12% 11.0% 16% 09% 06% 1.3% 0.9% 1.2%	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45]
Tyni-Lenner Gordon 96 Welengs 1998 Welengs 1999 CHANGE Subtotal (95% CI) Heterogeneity. Tau ² = 3.49, Civ ² 10 Duration of intervention >12.1 Belardroelli 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 2000 Keteyian 1996 Killanuori 1996 Ponkooski 1997	7 35 35 35 234 2 = 48.60, d P = 0.00015 weeks 11 9 9 31 15 12	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (3.8)	32 32 224 01); ² =71 46 14 9 9 33 14 15	-0.63 (3) -0.6 (3.4) % % -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) 0.5 (4)		12% 11.0% 11.0% 1.6% 0.9% 0.6% 1.3% 0.9% 1.2% 0.3% 0.7%	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.5, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36]
Tyni-Lenne/Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau² = 349; Cni² Test for overall effect 27 = 379 Gottlieb 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 2000 Kettyain 1996 Kildwun 1996 Ponikowski 1997 Welenga 1998 Wilenheimer 1998 Subtotal (95% CI)	7 35 35 234 234 8 8 8 8 8 11 9 9 31 15 12 16 35 22 208	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (3.05) -0.9 (2.6)	32 32 224 46 14 9 9 33 14 15 13 32 27	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) 0.5 (4) -0.63 (3)		12% 11.0 % 11.0 % 1.6% 0.9% 0.6% 1.3% 0.9% 0.3% 0.7% 1.2%	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.3, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-3.6, 0.36] -0.81 [-2.26, 0.64]
Tyni-Lenne/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity Tau* = 3.49, Civi Test for overall effect: 2 = 3.79 (Civi Bedurdinelli 1999 Jambor 1996 Hambrecht 1995 Hambrecht 1998 Hambrecht 1998 Hambrecht 1996 Kilbauori 1996 Kilbauori 1996 Willenbeimer 1998 Willenbeimer 1998 Subtotal (95% CI) Heterogeneity, Tau* = 2.33, Civi Subtotal (95% CI)	7 35 35 35 234 48 214 48 11 9 31 15 12 208	-1.44 (3.05) -1.4 (2.95) (= 14 (P = 0.000 5) -4.2 (1.55) -2.4 (2.8) -5.8 (3.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.3 (8) -1.44 (3.05) -0.9 (2.6) (= 9 (P-0.0000)	32 32 224 46 14 9 9 33 14 15 13 32 27	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) 0.5 (4) -0.63 (3)		12% 11.0% 11.0% 1.6% 0.9% 0.6% 1.3% 0.7% 1.2% 1.3%	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.40 [-6.53, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30]
Tyri-Lenner(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau ² = 349; Chri test for overall effect: Z = 379; Chri Belardinelli 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 2000 Keteyan 1996 Killauuri 1996 Ponikovski 1997 Wielenga 1998 Willenheimer 1998 Subtotal (95% CI) Heterogeneity: Tau ² = 233, Chri effer for overall effect: Z = 450 (s) Duration of intervention = 471	7 35 35 35 234 48 84 81 11 9 9 31 15 12 208 2208 200 200 200 200 200 200 200 2	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (3.05) -0.9 (2.6) f = 9 (P<0.0000) (1)	32 32 224 46 14 9 9 33 14 15 13 32 27 212 212 212	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) 0.5 (4) -0.63 (3) 0.1 (1.9)		12% 11.0 % 16% 09% 06% 1.3% 0.9% 1.2% 0.3% 0.7% 1.2% 1.3% 10.0 %	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -267] -2.30 [.444, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.100 [-2.30, 0.30] -2.62 [-3.76, -1.48]
Tyni-Lenner(Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity Tau ² = 3.49, Civ ² Duration of intervention >1.2 × Belarcinelli 1999 Gottieb 1999 Hambrecht 1995 Hambrecht 1996 Killavuori 1996 Killavuori 1996 Ponikowski 1997 Wielenga 1999 Wielenga 1999 Wielenga 1998 Subtotal (95% CI) Heterogeneity: Tau ² = 2.33, Chi ² est for overall effect Z = 4.50 Courailor of intervention =/<1 Belardinelli 1995	7 35 35 35 234 48 48 11 9 9 31 15 12 208 22 208 36 22 208 36 36 36 36 36 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38	-1.44 (3.05) -1.4 (2.95) =1.4 (P = 0.000 5) -42 (1.55) -24 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.9 (2.6) =9 (P<0.00001)) -1.15 (1.36)	32 32 224 46 14 9 9 33 14 15 13 32 27 212 212 19	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) 0.5 (4) -0.63 (3) 0.1 (1.9)		12% 11.0% 11.0% 16% 09% 06% 13% 09% 12% 03% 12% 13% 11.0%	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48]
Tyni-Lennel Gordon 96 Wielengs 1998 Wielengs 1999 CHANGE Subtotal (95% CI) -teterogeneity. Tau ¹ = 3.49, Civ ¹ Duration of intervention > 12.3 Belardinelli 1999 Gottliel 1999 Hambrecht 1995 Hambrecht 1995 Hambrecht 2000 Keteyian 1996 Killanueri 1996 Killanueri 1996 Vivielenga 1998 Willenheimer 1998 Vivielenga 1998 Vivielenga 1998 Villenheimer 1998 Subtotal (95% CI) -teterogeneity. Tau ¹ = 2.33, Chi ¹ liest for overall effect. Z = 4.50 (5 Duration of intervention = /< 1 Belardinelli 1995 Coats 1990	7 35 35 234 48 48,60,d, d,	-1.44 (3.05) -1.4 (2.95) (= 14 (P = 0.000 5) -4.2 (1.55) -2.4 (2.8) -3.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.3 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -1.44 (3.05) -0.9 (2.6) (= 9 (P = 0.00001) 1) -1.15 (1.36) -3.2 (3.8)	32 32 32 32 32 32 32 32 32 32 32 32 32 3	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (27) 0.7 (1.48) -0.3 (43) -0.5 (4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5)		12% 11.0 % 16.8 0.9% 0.6% 1.3% 0.7% 1.2% 1.3% 10.0 %	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48]
Tyni-Lenne/Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity, Tau ¹ = 3.49, Git- Est for overall effect Z = 3.79 (5) Duration of liferenerino >12.1 Belardinelli 1999 Gottlieb 1999 Hambrecht 1995 Hambrecht 1996 Kilavuori 1996 Kilavuori 1996 Kilavuori 1996 Villenheimer 1998 Subtotal (95% CI) Heterogeneity, Tau ² = 2.33; Chillest for overall effect Z = 4.50 (6) Duration of intervention =i<1 Belardinelli 1995 Coats 1990 Coats 1992	7 35 35 35 234 48 60 48 11 9 9 31 15 12 16 35 22 208 36 10 17	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 5) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -1.44 (3.05) -9.9 (2.6) f = 9 (P = 0.00001) 1) -1.15 (1.36) -3.2 (3.8) -2.4 (4.5)	32 32 32 224 46 46 49 9 33 32 14 15 13 32 27 212 212 19 10 17	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (43) -0.5 (1.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3)		12% 11.0 % 16.8 0.9% 0.6% 1.3% 0.7% 1.2% 13.3% 10.0 %	-0.81 [-226, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.45] -0.61 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48]
Tyni-Lenner Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI)	7 35 35 35 234 48 11 9 9 31 15 12 16 35 22 208 21 22 208 36 10 17	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 f) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -9 (2.6) f = 9 (P = 0.0000) f) -1.15 (1.36) -32 (3.8) -24 (4.5) -5.7 (4)	32 32 224 46 14 9 9 33 14 15 13 32 27 212 27 210 19 10 17 13	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.5 (1.87) 0.1 (5.4) 0.5 (4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1)		12% 11.0 % 11.0 % 1.6% 0.9% 0.6% 1.3% 0.7% 1.2% 1.3% 10.0 %	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.56] -4.70 [-7.88, -1.52]
Tyni-Lenner Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI)	7 35 35 35 234 8 = 48.60, d, d 11 9 9 31 15 12 16 35 22 208 21 = 42.50, d, d 10 17 12	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.000 f) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -1.44 (3.05) -0.9 (2.6) f = 9 (P = 0.00001)) -1.15 (1.36) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6)	32 32 32 32 32 32 32 32 32 32 32 32 32 3	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43)		12% 11.0 % 11.0 % 1.6% 0.9% 0.6% 1.3% 0.7% 1.2% 1.3% 10.0 % 1.5% 0.6% 0.6% 0.6%	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.40 [-6.5, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.56] -4.70 [-7.88, -1.52] -1.62 [-3.70, 6.8]
Tyni-Lenne/Gordon 96 Welenga 1998 Welenga 1999 CHANGE Welenga 1999 CHANGE Welenga 1999 CHANGE Heterogeneity: Tau* = 3.49. Chi* Test for overall effect 22 = 3.79 Gottleol 1999 Harborcht 1995 Harborcht 1998 Harborcht 1996 Killeuori 1996 Killeuori 1996 Fonkowski 1997 Wielenga 1998 Willenheimer 1998 Subtorad (95% CI) Heterogeneity: Tau* = 2.33. Chi* Test for overall effect 22 = 4.50 Coats 1990 Coats 1992 Dubach et al studies Jette 1991 Maiorana 2000	7 35 35 35 234 48 11 9 9 31 15 12 16 35 22 208 20 20 20 20 10 17 12 18	-1.44 (3.05) -1.4 (2.95) f = 14 (P = 0.0000) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -1.44 (3.05) -0.9 (2.6) f = 9 (P = 0.00001) -1.15 (1.36) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6)	32 32 224 46 14 9 9 9 33 14 15 13 32 27 212 27 19 10 17 13 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (43) -0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14)		12% 11.0% 11.0% 16% 09% 06% 13% 09% 12% 12% 13% 10.0%	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.3, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.56] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86]
Tyni-Lenner Gordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau² = 3.49; Chi² Test for overall effect 22 = 3.79 Gottleb 1999 Hambercht 1995 Hambercht 1996 Hambercht 1996 Hambercht 1996 Killeuori 1996 Killeuori 1996 Killeuori 1996 Willenheimer 1998 Willenheimer 1998 Subtotal (95% CI) Heterogeneity: Tau² = 2.33; Chi² Efferogeneity: Tau² = 2.33; Chi² Coats 1990 Coats 1990 Coats 1991 Dubach et al studies Jette 1991 Maiorana 2000 Meyer 1996	7 35 35 234 48 61 11 9 9 31 15 12 20 48 36 37 22 20 48 36 10 17 12 18 13	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2. (3.8) -1.44 (3.05) -0.9 (2.6) -1.15 (1.36) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7)	32 32 32 224 46 14 9 9 33 14 15 13 32 27 212 27 212 19 10 17 13 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (4.7) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7)		12% 11.0 % 11.0 % 16% 09% 06% 13% 09% 12% 13% 10.0 % 15.5% 06% 06% 08%	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-7.45, 2.45] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.80] -2.40 [-5.36, 0.80] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86] -2.50 [-5.86, 0.86]
Tyni-Lenner(Gordon 96 Welenga 1998 Welenga 1999 CHANGE Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity: Tau* = 3.49. Chi* Test for overall effect 27 = 3.79 Duration of intervention >12.1 Belardinellis 1999 Cottible 1999 Hambrecht 1998 Hambrecht 1998 Hambrecht 1996 Kiliaeuori 1996 Kiliaeuori 1996 Ponkowski 1997 Welenga 1998 Willenheimer 1998 Willenheimer 1998 Subtotal (95% CI) Heterogeneity: Tau* = 2.33, Chi* Effe for overall effect 27 = 450 (6 Duration of intervention	7 35 35 35 234 48 48 48 48 11 9 9 31 15 12 208 36 22 208 36 10 17 12 18 13 18	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.5 (2.3) -1.44 (3.05) -0.9 (2.6) -1.15 (1.36) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7) -0.52 (4.27)	32 32 32 224 46 14 9 9 33 31 41 15 13 32 27 212 217 219 10 17 13 18 18 18 18 18 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (18.7) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (15-4) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8)		12% 11.0% 11.0% 16% 09% 06% 13% 09% 12% 13% 10.0% 15% 06% 06% 06% 06% 06% 06%	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, 0.48] -2.50 [-7.45, 2.45] -2.50 [-7.45, 2.45] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.80] -2.40 [-5.36, 0.80] -2.40 [-5.36, 0.86] -2.50 [-5.86, 0.86] -2.50 [-5.86, 0.86] -2.00 [-5.25, 1.25] -0.52 [-3.16, 2.12]
Tyni-LennerGordon 96 Welenga 1998 Welenga 1999 CHANGE Subtotal (95% CI) Heterogeneity, Tau ¹ = 3.49, Civ ¹ Duration of intervention >12.3 Belardinelli 1999 Gottliel 1999 Hambrecht 1995 Hambrecht 1996 Killaruen 1996 Killaruen 1996 Killaruen 1996 Wilenheimer 1998 Wilenheimer 1998 Wilenheimer 1998 Subtotal (95% CI) Heterogeneity Tau ¹ = 2.33, Cni ¹ Test for overall effect Z = 4.50 Gottalon of intervention = I/< I Belardinelli 1995 Coats 1990 Coats 1990 Coats 1990 Dubach et al studies Jette 1991 Maiorana 2000 Meyer 1996 Oia 2000 Pu 2001	7 35 35 35 234 48 48 48 48 11 9 9 31 15 12 208 36 36 37 12 21 16 35 22 208 36 10 17 12 18 18 18	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -4.2 (1.55) -2.4 (2.8) -5.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -3.2 (3.8) -3.2 (3.8) -3.2 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7) -0.52 (4.27) -0.42 (4.1)	32 32 32 224 46 14 9 9 33 14 15 32 27 212 217 19 10 17 13 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (15-4) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8) -0.35 (2.74)		12% 11.0 % 11.0 % 16% 0.9% 0.6% 1.3% 0.7% 1.2% 1.3% 10.0 % 1.5% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.56] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86] -2.00 [-5.25, 1.25] -0.52 [-3.16, 2.12] -0.77 [-2.59, 4.13]
Tyni-Lenne/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Fleat for overall effect: 2 = 3.79 (Julie 1999) Hambrecht 1998 Hambrecht 1998 Hambrecht 1996 Killbauori 1996 Ponikowski 1997 Wielenga 1998 Willenheimer 1998 Willenheimer 1998 Subtotal (95% CI) Fleat for overall effect: Z = 4.50 (Druiton of intervention =/<1 Belardinelli 1995 Coats 1990 Coats 1990 Coats 1992 Dubach et al studies Jette 1991 Jette 1991 Jette 1996 Oka 2000 Pu 2001 Quittan 1999	7 35 35 35 234 48 60, d 11 9 9 31 15 12 16 35 228 28 10 17 12 18 13 18 18 18 9 11	-1.44 (3.05) -1.4 (2.95) = 14 (P = 0.000 5) -4.2 (1.55) -2.4 (2.8) -3.8 (3.6) -4.7 (1.17) -1.26 (4.3) -2.4 (7.3) -2. (3.8) -1.44 (3.05) -0.9 (2.6) = 9 (P = 0.00001) 1) -1.15 (1.36) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7) -0.52 (4.27) -0.42 (4.1) -2.6 (3)	32 32 32 224 46 14 9 9 33 14 15 32 27 212 219 10 17 13 18 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (4.3) -0.5 (1.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (15-4) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8) -0.35 (2.74) -0.7 (2.95)	*	12% 11.0 % 16.8% 0.9% 0.6% 1.3% 0.7% 1.2% 0.3% 0.7% 1.2% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6	-0.81 [-226, 0.64] -0.80 [-233, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, 0.48] -2.50 [-7.45, 2.45] -1.50 [-7.45, 2.45] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.36, 0.56] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.88] -2.50 [-5.86, 0.86] -2.00 [-5.25, 1.25] -0.52 [-3.16, 2.12] -0.77 [-2.59, 4.13] -1.90 [-4.33, 0.53]
Tyni-Lenne/Cordon 96 Welenga 1998 Welenga 1999 C-HANGE Welenga 1999 C-HANGE Welenga 1999 C-HANGE Heterogeneity. Tau? = 3.49, Cui- Test for overall effect. Z = 3.79 (J. 5 Duration of fretwerston > 12.1 Beduráneis 1999 Hambrecht 1995 Hambrecht 1996 Hambrecht 1996 Hambrecht 1996 Killavuori 1996 Ponikowski 1997 Welenga 1998 Willenheimer 1998 Subtotal (95% CI) Heterogeneity. Tau? = 2.33, Chi Test for overall effect. Z = 4.50 (d. Duration of fretwersten = <-I law of the company of the	7 35 35 32 234 48 60, d 48 11 9 9 31 15 12 16 35 22 208 36 10 17 12 18 13 18 18 18 9 11 8	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -2.4 (2.8) -3.8 (3.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7) -0.52 (4.27) -0.42 (4.1) -2.6 (3) -2 (2.35)	32 32 224 46 14 9 9 33 34 15 13 32 27 7 212 217 13 18 18 13 18 18 18 18 18 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.5 (1.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8) -0.35 (2.74) -0.7 (2.95) 0.1 (1.8)		12% 11.0 % 1.6% 0.9% 0.6% 1.3% 0.7% 1.2% 0.38 0.7% 1.2% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.80, 0.86] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86] -2.00 [-5.25, 1.25] -0.52 [-3.16, 2.12] -0.77 [-2.59, 4.13] -1.90 [-4.33, 0.53] -2.10 [-4.15, -0.05]
Tyni-Lenne/Cordon 96 Wielenga 1998 Wielenga 1999 C-HANGE Wielenga 1999 C-HANGE Wielenga 1999 C-HANGE Wielenga 1999 C-HANGE Heterogeneity Tau? = 3.49, Cit- Test for overall effect. Z = 3.79 (Gottleb 1999 Hambrecht 1995 Hambrecht 1998 Hambrecht 1998 Hambrecht 1996 Killaruori 1996 Ponikowski 1997 Wielenga 1998 Willenbeimer 1998 Subtotal (95% CI) Heterogeneity Tau? = 2.33, Cit- Test for overall effect. Z = 4.50 (Gottleb) Coats 1990 Coats 1992 Dubach et al studies Jette 1991 Maiorana 2000 Meyer 1996 Ola 2000 Pu 2001 Quittan 1999 Tyni-Lenne 1997 Tyni-Lenne 1997 Tyni-Lenne 2001	7 35 35 32 234 48 11 9 9 31 15 12 16 35 22 22 20 81 36 10 17 12 18 13 18 18 18 19 11 8 16	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -2.4 (2.8) -3.8 (3.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -3.2 (3.8) -1.44 (3.05) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7.7) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -2.6 (3) -1.1 (4.24)	32 32 32 32 46 14 9 9 33 33 14 15 13 32 27 7 212 19 10 17 13 18 13 18 13 18 13 18 18 18 18 18 18 18 18 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.3 (43) -0.5 (1.87) 0.1 (5.4) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8) -0.35 (2.74) -0.7 (2.95) 0.1 (1.8) 1.6 (3.45)		12% 11.0 % 1.6 % 0.9 % 0.6 % 1.3 % 0.7 % 1.2 % 1.3 % 10.0 % 1.5 % 0.6 % 0.6 % 0.6 % 0.6 % 0.5 % 0.6 % 0.5 % 0.6 % 0.7 % 0.5 % 0.6 % 0.7 % 0.7 % 0.8 % 0.8 % 0.9 % 0.9 % 0.9 % 0.9 % 0.9 % 0.0 %	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.53, -4.17] -0.96 [-3.07, 1.15] -2.50 [-3.52, -0.48] -2.50 [-3.52, -0.48] -1.50 [-2.26, 0.64] -1.50 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.60, 0.80] -2.40 [-5.52, 1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86] -0.50 [-5.25, 1.52] -0.52 [-3.16, 2.12] -0.77 [-2.59, 4.13] -1.90 [-4.33, 0.53] -2.10 [-4.15, -0.05] -2.70 [-5.87, 0.47]
Tyni-Lennel/Gordon 96 Wielenga 1998 Wielenga 1999 CHANGE Subtotal (95% CI) Heterogeneity, Tau' = 349, Civ' Test for overall effect; Z = 3.79 (C) Southern (1998) Hambrecht 1995 Hambrecht 1996 Hambrecht 1996 Killaruori 1996 Ponikowski 1997 Wielenga 1998 Willenheimer 1998 Subtroll (95% CI) Fatt for overall effect; Z = 4.50 (G) Dutation of intervention = /< I Subtroll (95% CI) Fatt for overall effect; Z = 4.50 (G) Coats 1990 Coats 1990 Coats 1992 Dubach et al studies Jette 1991 Maiorana 2000 Major 1996 Civa 2000 Pu 2001 Quittan 1999 Tyni-Lenne 1997	7 35 35 32 234 48 60, d 48 11 9 9 31 15 12 16 35 22 208 36 10 17 12 18 13 18 18 18 9 11 8	-1.44 (3.05) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -1.4 (2.95) -2.4 (2.8) -3.8 (3.17) -1.26 (4.3) -2.5 (2.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -2.4 (7.3) -3.2 (3.8) -2.4 (4.5) -5.7 (4) -1.52 (3.6) -2.6 (4.6) -2.4 (7) -0.52 (4.27) -0.42 (4.1) -2.6 (3) -2 (2.35)	32 32 224 46 14 9 9 33 34 15 13 32 27 7 212 217 13 18 18 13 18 18 18 18 18 18 18 18 18 18	-0.63 (3) -0.6 (3.4) % -0.8 (2) -0.1 (2.6) 0 (2.7) 0.7 (1.48) -0.5 (1.87) 0.1 (5.4) -0.63 (3) 0.1 (1.9) 0.8 (1.54) -0.8 (3.5) 0 (4.3) -1 (4.1) 0.1 (3.43) -0.1 (4.14) -0.4 (0.7) 0 (3.8) -0.35 (2.74) -0.7 (2.95) 0.1 (1.8)		12% 11.0 % 1.6% 0.9% 0.6% 1.3% 0.7% 1.2% 0.38 0.7% 1.2% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6	-0.81 [-2.26, 0.64] -0.80 [-2.33, 0.73] -2.28 [-3.47, -1.10] -3.40 [-4.13, -2.67] -2.30 [-4.44, -0.16] -5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17] -0.96 [-3.07, 1.15] -2.00 [-3.52, -0.48] -2.50 [-7.45, 2.45] -2.50 [-5.36, 0.36] -0.81 [-2.26, 0.64] -1.00 [-2.30, 0.30] -2.62 [-3.76, -1.48] -1.95 [-2.77, -1.13] -2.40 [-5.60, 0.80] -2.40 [-5.80, 0.86] -4.70 [-7.88, -1.52] -1.62 [-3.92, 0.68] -2.50 [-5.86, 0.86] -2.00 [-5.25, 1.25] -0.52 [-3.16, 2.12] -0.77 [-2.59, 4.13] -1.90 [-4.33, 0.53] -2.10 [-4.15, -0.05]

10.3 % -1.79 [-2.33, -1.24]

total (95% CI) 228 200 rogeneity: Tau² = 0.0; Chi² = 9.25, df = 13 (P = 0.75); l² = 0.0%

Subtotal (95% CI)

T-16	0.00001	15					
Test for overall effect: Z = 6.45 (F 7 Mean age > 55 years	P < 0.00001	1)					
Belardinelli 1999	48	-4.2 (1.55)	46	-0.8 (2)	-	1.6 %	-3.40 [-4.13, -2.67]
Coats 1990	10	-3.2 (3.8)	10	-0.8 (3.5)		0.6 %	-2.40 [-5.60, 0.80]
Coats 1992	17	-2.4 (4.5)	17	0 (4.3)		0.6 %	-2.40 [-5.36, 0.56]
Gottlieb 1999	11	-2.4 (2.8)	14	-0.1 (2.6)		0.9 %	-2.30 [-4.44, -0.16]
Maiorana 2000	13	-2.6 (4.6)	13	-0.1 (4.14)		0.5 %	-2.50 [-5.86, 0.86]
Oka 2000	18	-0.52 (4.27)	18	0 (3.8)		0.7 %	-0.52 [-3.16, 2.12]
Ponikowski 1997	16	-2 (3.8)	13	0.5 (4)		0.7 %	-2.50 [-5.36, 0.36]
Pu 2001	9	0.42 (4.1)	7	-0.35 (2.74)		0.5 %	0.77 [-2.59, 4.13]
Quittan 1999 Tyni-Lenne 1997	11	-2.6 (3) -2 (2.35)	12	-0.7 (2.95)		0.8 %	-1.90 [-4.33, 0.53]
Tyni-Lenne 2001	16	-1.1 (4.24)	8	0.1 (1.8)		0.9 %	-2.10 [-4.15, -0.05] -2.70 [-5.87, 0.47]
Tyni-Lenne/Gordon 96	7	-0.5 (2.83)	7	0.3 (4.6)		0.6 %	-0.80 [-4.80, 3.20]
Wielenga 1998	35	-1.44 (3.05)	32	-0.63 (3)		1.2 %	-0.81 [-2.26, 0.64]
Wielenga 1999 CHANGE	35	-1.4 (2.95)	32	-0.6 (3.4)		1.2 %	-0.80 [-2.33, 0.73]
Willenheimer 1998	22	-0.9 (2.6)	27	0.1 (1.9)	-	1.3 %	-1.00 [-2.30, 0.30]
Subtotal (95% CI)	276	(2.2)	264	()	•	12.5 %	-1.77 [-2.50, -1.03]
Heterogeneity: Tau ² = 0.79; Chi ²			3); 12 =46%				
Test for overall effect: Z = 4.73 (ii 8 Mean age =/< 55 years	P < 0.00001	1)					
Belardinelli 1995	36	-1.15 (1.36)	19	0.8 (1.54)	-	1.5 %	-1.95 [-2.77, -1.13]
Dubach et al studies	12	-5.7 (4)	13	-1 (4.1)		0.6 %	-4.70 [-7.88, -1.52]
Hambrecht 1995	9	-5.8 (3.6)	9	0 (2.7)		0.6 %	-5.80 [-8.74, -2.86]
Hambrecht 1998	9	-4.7 (1.17)	9	0.7 (1.48)	-	1.3 %	-5.40 [-6.63, -4.17]
Hambrecht 2000	31	-1.26 (4.3)	33	-0.3 (4.3)	-	0.9 %	-0.96 [-3.07, 1.15]
Jette 1991	18	-1.52 (3.6)	18	0.1 (3.43)	-	0.8 %	-1.62 [-3.92, 0.68]
Keteyian 1996	15	-2.5 (2.3)	14	-0.5 (1.87)		1.2 %	-2.00 [-3.52, -0.48]
Kiilavuori 1996	12	-2.4 (7.3)	15	0.1 (5.4)	-	0.3 %	-2.50 [-7.45, 2.45]
Meyer 1996	18	-2.4 (7)	18	-0.4 (0.7)		0.6 %	-2.00 [-5.25, 1.25]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.52; Chi ²	160 = 31.81, dt	f = 8 (P = 0.000	148 010): 1 ² =75%	5	•	7.9 %	-2.95 [-4.25, -1.64]
Test for overall effect: Z = 4.43 (F	P < 0.00001		,				
9 Duration of follow up > 16 we	eks						
					550 I		
Belardinelli 1995	36	-1.15 (1.36)	19	0.8 (1.54)	-	1.5 %	-1.95 [-2.77, -1.13]
Belardinelli 1999	48	-4.2 (1.55)	46	-0.8 (2)		1.6 %	-3.40 [-4.13, -2.67]
Gottlieb 1999 Hambrecht 1995	9	-2.4 (2.8)	14	-0.1 (2.6)		0.9 %	-2.30 [-4.44, -0.16]
Hambrecht 1998	9	-5.8 (3.6) -4.7 (1.17)	9	0 (2.7)		1.3 %	-5.80 [-8.74, -2.86] -5.40 [-6.63, -4.17]
Hambrecht 2000	31	-1.26 (4.3)	33	-0.3 (4.3)		0.9 %	-0.96 [-3.07, 1.15]
Keteyian 1996	15	-2.5 (2.3)	14	-0.5 (1.87)		1.2 %	-2.00 [-3.52, -0.48]
Kiilavuori 1996	12	-2.4 (7.3)	15	0.1 (5.4)		0.3 %	-2.50 [-7.45, 2.45]
Wielenga 1998	35	-1.44 (3.05)	32	-0.63 (3)		1.2 %	-0.81 [-2.26, 0.64]
Subtotal (95% CI)	206		191	(-)	•	9.6 %	-2.74 [-3.83, -1.65]
Heterogeneity: Tau ² = 1.88; Chi ² :			1); 12 =80%				
Test for overall effect: Z = 4.94 (P)					
10 Duration of follow up =/< 16 v Coats 1990	weeks 10	-3.2 (3.8)	10	-0.8 (3.5)		0.6 %	-2.40 [-5.60, 0.80]
Coats 1992	17	-2.4 (4.5)	17	0 (4.3)		0.6 %	-2.40 [-5.36, 0.56]
Dubach et al studies	12	-5.7 (4)	13	-1 (4.1)		0.6 %	-4.70 [-7.88, -1.52]
Jette 1991	18	-1.52 (3.6)	18	0.1 (3.43)		0.8 %	-1.62 [-3.92, 0.68]
Maiorana 2000	13	-2.6 (4.6)	13	-0.1 (4.14)		0.5 %	-2.50 [-5.86, 0.86]
Meyer 1996	18	-2.4 (7)	18	-0.4 (0.7)		0.6 %	-2.00 [-5.25, 1.25]
Oka 2000	18	-0.52 (4.27)	18	0 (3.8)		0.7 %	-0.52 [-3.16, 2.12]
Panikowski 1997	16	-2 (3.8)	13	0.5 (4)		0.7 %	-2.50 [-5.36, 0.36]
Pu 2001	9	0.42 (4.1)	7	-0.35 (2.74)		0.5 %	0.77 [-2.59, 4.13]
Quittan 1999	11	-2.6 (3)	12	-0.7 (2.95)		0.8 %	-1.90 [-4.33, 0.53]
Tyni-Lenne 1997	8	-2 (2.35)	8	0.1 (1.8)	-	0.9 %	-2.10 [-4.15, -0.05]
Tyni-Lenne 2001	16	-1.1 (4.24)	8	1.6 (3.45)		0.6 %	-2.70 [-5.87, 0.47]
Tyni-Lenne/Gordon 96	7	-0.5 (2.83)	7	0.3 (4.6)		0.4 %	-0.80 [-4.80, 3.20]
Wielenga 1999 CHANGE	35	-1.4 (2.95)	32	-0.6 (3.4)	-	1.2 %	-0.80 [-2.33, 0.73]
Willenheimer 1998	22	-0.9 (2.6)	27	0.1 (1.9)		1.3 %	-1.00 [-2.30, 0.30]
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0; Chi ² =	230	: 14 (P = 0.75)-	221 12 =0.0%		•	10.8 %	-1.55 [-2.17, -0.94]
Test for overall effect: $Z = 4.93$ (P	< 0.00001)						Solicional de successor
Total (95% CI) Heterogeneity: Tau ² = 1.25; Chi ² :	2154 = 305.75 d	f = 117 /P<00	2037	196	•	100.0 %	-2.19 [-2.48, -1.90]
	555, C	(~~0.0	- 20 - 71 1 - 02				



WHAT'S NEW

Last assessed as up-to-date: 17 May 2004.

Date	Event	Description
8 September 2008	Amended	Converted to new review format.

HISTORY

Protocol first published: Issue 4, 2001

Review first published: Issue 3, 2004

Date	Event	Description
18 May 2004	New citation required and conclusions have changed	Substantive amendment

References to studies included in this review

Belardinelli 1992 {published data only} . Belardinelli R, Scocco V, Mazzanti M, et al. Effects of aerobic training in patients with moderate chronic heart failure. Giornale italiano di cardiologia. 1992; 22(8):919–30. [PubMed: 1478392]

Belardinelli 1995 {published data only} . Belardinelli R, Georgiou D, Cianci G, Berman N, Ginzton L, Purcaro A. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation. 1995; 91(11):2775–84. [PubMed: 7758184]

Belardinelli 1999 {published data only} . Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999; 99(9): 1173–82. [PubMed: 10069785]

Cider 1997 {published data only} . Cider A, Tygesson H, Hedberg M, Seligman L, Wennerblom B, Sunnerhagen KS. Peripheral muscle training in patients with clinical signs of heart failure. Scandinavian Journal of Rehabilitation Medicine. 1997; 29(2):121–7. [PubMed: 9198262]

Coats 1990 {published data only} . Coats A, Adamopoulos S. A cross-over comparison of outpatient physical training versus rest in the treatment of moderate to severe heart failure [abstract]. Clinical Science. 1989; 77(Suppl 21):19P.

Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. Lancet. 1990; 335(8681):63–6. [PubMed: 1967416]

Coats 1992 {published data only} . Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992; 85(6): 2119–31. [PubMed: 1591831]

Dubach et al studies {published data only} . Callaerts-Vegh Z, Wenk M, Goebbels U, Dziekan G, Myers J, Dubach P, et al. Influence of intensive physical training on urinary nitrate elimination and plasma endothelin-1 levels in patients with congestive heart failure. Journal of Cardiopulmonary Rehabilitation. 1998; 18(6):450–7. [PubMed: 9857278]

- Dubach P, Myers J, Dziekan G, Goebbels U, Reinhart W, Muller P, et al. Effect of high intensity exercise training on central hemodynamic responses to exercise in men with reduced left ventricular function. Journal of the American College of Cardiology. 1997; 29(7):1591–8. [PubMed: 9180124]
- Duru F, Candinas R, Dziekan G, Goebbels U, Myers J, Dubach P. Effect of exercise training on heart rate variability in patients with new-onset left ventricular dysfunction after myocardial infarction. American Heart Journal. 2000; 140(1):157–61. [PubMed: 10874279]
- Dziekan G, Myers J, Goebbels U, Muller P, Reinhart W, Ratti R, et al. Effects of exercise training on limb blood flow in patients with reduced ventricular function. American Heart Journal. 1998; 136(1):22–30. [PubMed: 9665214]
- Goebbels U, Myers J, Dziekan G, Muller P, Kuhn M, Ratte R, et al. A randomized comparison of exercise training in patients with normal vs reduced ventricular function. Chest. 1998; 113(5): 1387–93. [PubMed: 9596323]
- Myers J, Gianrossi R, Schwitter J, Wagner D, Dubach P. Effect of exercise training on postexercise oxygen uptake kinetics in patients with reduced ventricular function. Chest. 2001; 120(4):1206–11. [PubMed: 11591562]
- Myers J, Goebbels U, Dzeikan G, Froelicher V, Bremerich J, Mueller P, et al. Exercise training and myocardial remodeling in patients with reduced ventricular function: One-year follow-up with magnetic resonance imaging. American Heart Journal. 2000; 139(21):252–61. [PubMed: 10650298]
- Gottlieb 1999 {published data only} . Gottlieb SS, Fisher ML, Freudenberger R, Robinson S, Zietowski G, Alves L, et al. Effects of exercise training on peak performance and quality of life in congestive heart failure patients. Journal of Cardiac Failure. 1999; 5(3):188–94. [PubMed: 10496191]
- Hambrecht 1995 {published data only} . Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. Journal of the American College of Cardiology. 1995; 25(6):1239–49. [PubMed: 7722116]
- Hambrecht 1998 {published data only} . Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998; 98(24):2709–15. [PubMed: 9851957]
- Hambrecht 2000 {published data only} . Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA. 2000; 283(23):3095–101. [PubMed: 10865304]
- Jette 1991 {published data only} . Jette M, Heller R, Landry F, Blumchen G. Randomized 4 week exercise program in patients with impaired left ventricular function. Circulation. 1991; 84(4): 1561–7. [PubMed: 1914097]
- Keteyian 1996 {published data only} . Keteyian SJ, Levine AB, Brawner CA, Kataoka T, Rogers FJ, Schairer JR, et al. Exercise training in patients with heart failure. A randomized, controlled trial. Annals of Internal Medicine. 1996; 124(12):1051–7. [PubMed: 8633818]
- Kiilavuori 1996 {published data only} . Kiilavuori K, Sovijarvi A, Naveri H, Ikonen T, Leinonen H. Effect of physical training on exercise capacity and gas exchange in patients with chronic heart failure. Chest. 1996; 110(4):985–91. [PubMed: 8874256]
- Maiorana 2000 {published data only} . Maiorana A, O'Driscoll G, Cheetham C, Collis J, Goodman C, Rankin S, et al. Combined aerobic and resistance exercise training improves functional capacity and strength in CHF. Journal of Applied Physiology. 2000; 88(5):1565–70. [PubMed: 10797113]
- Meyer 1996 {published data only} . Meyer K, Schwaibold M, Westbrook S, Beneke R, Hajric R, Gornandt L, et al. Effects of short-term exercise training and activity restriction on functional

- capacity in patients with severe chronic congestive heart failure. American Journal of Cardiology. 1996; 78(9):1017–22. [PubMed: 8916481]
- Meyer K, Schwaibold M, Westbrook S, Beneke R, Hajric R, Lehmann M, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. American Heart Journal. 1997; 133(4):447–53. [PubMed: 9124167]
- Oka 2000 {published data only} . Oka RK, De Marco T, Haskell WL, Botvinick E, Dae MW, Bolen K, et al. Impact of a home-based walking and resistance training program on quality of life in patients with heart failure. American Journal of Cardiology. 2000; 85(3):365–9. [PubMed: 11078308]
- Owen 2000 {published data only} . Owen A, Croucher L. Effect of an exercise programme for elderly patients with heart failure. European Journal of Heart Failure. 2000; 2(1):65–70. [PubMed: 10742705]
- Parnell 2002 {published data only} . Parnell MM, Holst DP, Kaye DM. Exercise training increases arterial compliance in patients with congestive heart failure. Clinical Science. 2002; 102(1):1–7. [PubMed: 11749654]
- Ponikowski 1997 {published data only} . Ponikowski P, Szelemej R, Kowalska-Superlak M, Kratochwil D, Sobkowicz B, Sebzda T, et al. Exercise rehabilitation in patients with moderate-severe chronic heart failure. [CZY CHORZY Z NIEWYDOLNOSCIA KRAZENIA KORZYSTAJA Z REHABILITACJI RUCHOWEJ?]. Kardiologia Polska. 1997; 47(10):291–300.
- Pu 2001 {published data only} . Pu CT, Johnson MT, Forman DE, Hausdorff JM, Roubenoff R, Foldvari M, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. Journal of Applied Physiology. 2001; 90(6):2341–50. [PubMed: 11356801]
- Quittan 1999 {published data only} . Quittan M, Sturm B, Wiesinger GF, Pacher R, Fialka-Moser V. Quality of life in patients with chronic heart failure: a randomized controlled trial of changes induced by a regular exercise program. Scandinavian Journal of Rehabilitation Medicine. 1999; 31(4):223–8. [PubMed: 10599899]
- Sturm B, Quittan M, Wiesinger GF, Stanek B, Frey B, Pacher R. Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure. Archives of physical medicine and rehabilitation. 1999; 80:746–50. [PubMed: 10414756]
- Teo 1995 EXERT {published data only} . McKelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T, Hendrican K, Yusuf S. Effects of exercise training in patients with heart failure: The Exercise Rehabilitation Trial (EXERT). American heart journal. 2002; 144(23-30)
- Teo K, McKelvie R, Yusuf S, McCartney N, Guyatt G, Roberts R, et al. Randomized controlled trial of aerobic plus resistance exercise training in patients with congestive heart failure. The Exercise Rehab Trial (EXERT) Investigators [abstract]. Controlled clinical trials. 1995; 16(3 Suppl):99S.
- Tyni-Lenne 1997 {published data only} . Tyni-Lenne R, Gordon A, Jansson E, Bermann G, Sylven C. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. American Journal of Cardiology. 1997; 80(8):1025–9. [PubMed: 9352972]
- Tyni-Lenne 2001 {published data only} . Tyni-Lenne R, Dencker K, Gordon A, Jansson E, Sylven C. Comprehensive local muscle training increases aerobic working capacity and quality of life and decreases neurohormonal activation in patients with chronic heart failure. European Journal of Heart Failure. 2001; 3(1):47–52. [PubMed: 11163735]
- Tyni-Lenne/Gordon 96 {published data only} . Gordon A, Tyni-Lenne R, Persson H, Kaijser L, Hultman E, Sylven C. Markedly improved skeletal muscle function with local muscle training in patients with chronic heart failure. Clinical Cardiology. 1996; 19(7):568–74. [PubMed: 8818438]
- Tyni-Lenne R, Gordon A, Sylven C. Improved quality of life in chronic heart failure patients following local endurance training with leg muscles. Journal of Cardiac Failure. 1996; 2(2):111–7. [PubMed: 8798112]
- Wielenga 1998 {published data only} Wielenga RP, Huisveld IA, Bol E, Dunselman PH, Erdman RA, Baselier MR, et al. Exercise training in elderly patients with chronic heart failure [published

- erratum appears in Coron Artery Dis. 1999; 10(1):57.Coronary Artery Disease. 1998; 9(11):765–70. [PubMed: 9919425]
- Wielenga 1999 CHANGE {published data only} . Wielenga RP, Huisveld IA, Bol E, Dunselman PH, Erdman RA, Baselier MR, et al. Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE). European Heart Journal. 1999; 20(12):872–9. [PubMed: 10329092]
- Willenheimer 1998 {published data only} . Willenheimer R, Erhardt L, Cline C, Rydberg E, Israelsson B. Exercise training in heart failure improves quality of life and exercise capacity. European Heart Journal. 1998; 19(5):774–81. [PubMed: 9717012]

References to studies excluded from this review

- Adamopoulos 1995 {published data only} . Adamopoulos S, Ponikowski P, Cerquetani E, Piepoli M, Rosano G, Sleight P, et al. Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. European Heart Journal. 1995; 16(10):1380–6. [PubMed: 8746907]
- Barnard 2000 {published data only} . Barnard KL, Adams KJ, Swank AM, Kaelin M, Kushnik MR, Denny DM. Combined high-intensity strength and aerobic training in patients with congestive heart failure. Journal of strength and conditioning research. 2000; 14:383–8.
- Belardinelli2 1995 {published data only} . Belardinelli R, Georgiou D, Scocco V, Barstow TJ, Purcaro A. Low intensity exercise training in patients with chronic heart failure. Journal of the American College of Cardiology. 1995; 26(4):975–82. [PubMed: 7560627]
- Cohen-Solal 1994 {published data only} . Cohen-Solal A, Aupetit JF, Gueret P, Kolsky H, Zannad F, The VO2 French Study Group. Can anaerobic threshold be used as an end-point for therapeutic trials in heart failure? Lessons from a multicentre randomized placebo-controlled trial. European Heart Journal. 1994; 15(2):236–41. [PubMed: 8005126]
- Davey 1992 {published data only} . Davey P, Meyer T, Coats A, Adamopoulos S, Casadei B, Conway J, et al. Ventilation in chronic heart failure: Effects of physical training. British heart journal. 1992; 68(5):473–7. [PubMed: 1467031]
- Gordon 1999 {published data only} . Gordon A, Tyni-Lenne R, Jansson E, Jensen-Urstad M, Kaijser L. Beneficial effects of exercise training in heart failure patients with low cardiac output response to exercise a comparison of two training models. Journal of Internal Medicine. 1999; 246(2):175–82. [PubMed: 10447786]
- Johnson 1998 {published data only} . Johnson PH, Cowley AJ, Kinnear WJ. A randomized controlled trial of inspiratory muscle training in stable chronic heart failure. European Heart Journal. 1998; 19(8):1249–53. [PubMed: 9740347]
- Kavanagh 1996 {published data only} . Kavanagh T, Myers MG, Baigrie RS, Mertens DJ, Sawyer P, Shephard RJ. Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months' aerobic training. Heart. 1996; 76(1):42–9. [PubMed: 8774326]
- Koch 1992 {published data only} . Koch M, Douard H, Broustet JP. The benefit of graded physical exercise in chronic heart failure. Chest. 1992; 101(5 Suppl):231S–235S. [PubMed: 1576841]
- Metra 1998 {published data only} . Metra M, Nodari S, Raccagni D, Garbellini M, Boldi E, Bontempi L, et al. Maximal and submaximal exercise testing in heart failure. Journal of Cardiovascular Pharmacology. 1998; 32(Suppl 1):S36–S45. [PubMed: 9731694]
- Page 1994 {published data only} . Page E, Cohen-Solal A, Jondeau G, Douard H, Roul G, Kantelip JP, et al. Comparison of treadmill and bicycle exercise in patients with chronic heart failure. Chest. 1994; 106(4):1002–6. [PubMed: 7924466]
- Taylor 1999 {published data only} . Taylor A. Physiological response to a short period of exercise training in patients with chronic heart failure. Physiotherapy Research International. 1999; 4(4): 237–49. [PubMed: 10633526]
- Tokmakova 1999 {published data only} . Tokmakova M, Dobreva B, Kostianev S. Effects of short-term exercise training in patients with heart failure. Folia Medica (Plovdiv). 1999; 41(1): 68–71.

Tyni-Lenne 1998 {published data only} . Tyni-Lenne R, Gordon A, Europe E, Jansson E, Sylven C. Exercise-based rehabilitation improves skeletal muscle capacity, exercise tolerance, and quality of life in both women and men with chronic heart failure. Journal of Cardiac Failure. 1998; 4(1):9–17. [PubMed: 9573499]

Tyni-Lenne 1999 {published data only} . Tyni-Lenne R, Gordon A, Jensen-Urstad M, Dencker K, Jansson E, Sylven C. Aerobic training involving a minor muscle mass shows greater efficiency than training involving a major muscle mass in chronic heart failure patients. Journal of Cardiac Failure. 1999; 5(4):300–7. [PubMed: 10634671]

References to studies awaiting assessment

Kayanakis 1994 {published data only} . Kayanakis JG, Page E, Aros F, Borau F. [Rehabilitation of patients with chronic cardiac insufficiency. Immediate and midterm effects]. [French]. Presse Medicale. 1994; 23(3):121–6.

References to ongoing studies

- NRR ongoing trial 1 {published data only} . EXIST Exercise Intervention Strategies in Heart Failure Trial. National Research Register, Publication ID N0201112792Start date 01/07/2002, end date 31/12/2002
- NRR ongoing trial 2 {published data only} . A randomised trial of exercise intervention for older patients with heart failure. National Research Register, Publication ID NO514100933Start date 01/01/2001, end date 01/01/2004

Additional references

- AHA . American Heart Association. www.americanheart.org
- CHF Guidelines 2001 . Working Group on Cardiac Rehabilitation and Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. European Heart Journal. 2001; 22:125–35. [PubMed: 11161914]
- CHF Taskforce 2001 . The task force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal. 2001; 22:1527–60. [PubMed: 11492984]
- Cochrane Heart Group . Cochrane Heart Group. [Accessed May 2004] Preferred method for handling continuous variables. http://www.epi.bris.ac.uk/cochrane/stats3.html
- Conn 1982 . Conn EH, Williams RS, Wallace AG. Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. The American Journal of Cardiology. 1982; 49:296–300. [PubMed: 7058745]
- Cowie 1997 . Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in the assessment of patients with possible new hear failure in primary care. Lancet. 1997; 350:1349– 53. [PubMed: 9365448]
- Dickersin 1994 . Dickersin K, Scherer R, Lefebve C. Identifying relevant studies for systematic reviews. BMJ. 1994; 309:1286–91. [PubMed: 7718048]
- DOH 2000 . National Service Framework for Coronary Heart Disease. http://www.doh.gov.uk/pdfs/chdnsf.pdf
- Drexler 1992 . Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992; 85:1751–9. [PubMed: 1315220]
- Dziekan 1998 . Dziekan G, Myers J, Goebbels U, Muller P, Reinhart W, Ratti R, et al. Effects of exercise training on limb blood flow in patients with reduced ventricular function. American Heart Journal. 1998; 136:22–7. [PubMed: 9665214]
- Follmann 1992 . Follman D, Elliot P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology. 1992; 45:769–73. [PubMed: 1619456]

Hülsmann 2002 . Hülsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein, et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota living with heart failure questionnaire in an outpatient cohort with congestive heart failure. European Heart Journal. 2002; 23:886–91. [PubMed: 12042010]

- Jadad 1996 . Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of clinical trials: Is blinding necessary? Controlled Clinical Trials. 1996; 17(1):1–12. [PubMed: 8721797]
- Jolliffe 2001 . Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise based rehabilitation for coronary heart disease (Cochrane Review). The Cochrane Library. 2001; (2)
- Kannel 1991 . Kannel WB, Belanger AJ. Epidemiology of heart failure. American Heart Journal. 1991; 121:951–7. [PubMed: 2000773]
- Kostis 1997 . Kostis JB, Davis BR, Cutler J, et al. SHEP Cooperative Research Group. Prevention of heart failure antihypertensive drug treatment in older persons with isolated systemic hypertension. JAMA. 1997; 278(3):212–6. [PubMed: 9218667]
- Lee 1979 . Lee AP, Ice R, Blessey R, Sanmarco ME. Long term effects of physical training on coronary patients with impaired ventricular function. Circulation. 1979; 60(1519-26)
- Lefebvre 1996 . Lefebvre, C.; McDonald, S. Development of a sensitive search strategy for reports of randomised controlled trials in EMBASE; Conference Abstracts for the Fourth International Cochrane Colloquium; Adelaide, Australia. 1996; Oct 20-24.
- Lip 2000 . Lip GYH, Gibbs CR, Beevers DG. Aetiology: ABC of heart failure. BMJ. 2000; 320:104–7. [PubMed: 10625270]
- Lloyd-Williams 2002 . Lloyd-Williams F, Mair FS, Leitner M. Exercise training and heart failure: A systematic review of current evidence. British Journal of General Practice. 2002; 52(474):47–55. [PubMed: 11791816]
- Mancini 1992 . Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992; 85:1364–73. [PubMed: 1555280]
- McMurray 2000 . McMurray JJ, Steward S. Heart failure: Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000; 83:596–602. [PubMed: 10768918]
- NHS 1998 . NHS Centre for Reviews and Dissemination. Cardiac Rehabilitation. Effective Health Care Bulletin. 1998; 4
- O'Connor 1989 . O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation. 1989; 80:234–44. [PubMed: 2665973]
- Oldridge 1988 . Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomised clinical trials. JAMA. 1988; 260:945–50. [PubMed: 3398199]
- Opasich 2001 . Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, et al. Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? European Heart Journal. 2001; 22(6):445–8. [PubMed: 11237537]
- Rees 2004 . Rees K, Bennett PD, West RR, Davey-Smith G, Ebrahim S. Psychological Interventions for coronary heart disease. The Cochrane Library. 2004; (2)
- Sullivan 1988 . Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation. 1988; 78:506–15. [PubMed: 3409495]
- Sullivan 1989 . Sullivan MJ, Knight D, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Circulation. 1989; 80:769–81. [PubMed: 2791242]
- van den Brock 1992 . van den Brock SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hillege H, Lie KI. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology. 1992; 70:359–63. [PubMed: 1632403]

Watson 2000 . Watson RDS, Gibbs CR, Lip GYH. ABC of heart failure: clinical features and complications. BMJ. 2000; 320:236–9. [PubMed: 10642237]

*Indicates the major publication for the study

PLAIN LANGUAGE SUMMARY

Exercise training improves exercise tolerance and quality of life in people with mild to moderate heart failure

People with heart failure experience breathlessness and restricted activities of daily living because of their restricted heart capacity. This can reduce their amount of exercise, which can further reduce fitness, making their symptoms worse. The review found short-term trials of exercise training in people with mild to moderate heart failure only, which do not represent most of the people who have heart failure. The kinds of exercise programs varied greatly, but most included aerobic exercise rather than resistance training (such as working with weights). Exercise improved people's fitness and quality of life, without causing harm.